
Merck & Co., Inc.
MRKHealthcare|Drug Manufacturers - General|US
$146.71
-0.23 (-0.16%)
DCF Value
$180.27
Graham Number
$20.09
Cash / Share
$3.89
Clinical Trials (768)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06658522 Right Ventricular Compensation With Sotatercept: A Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension (RECOMPENSE) | Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I | P4 | Recruiting | 20 | Open-label | Sotatercept |
| NCT05992480 REVIVE (Response to the Ebola Virus Vaccine) | Ebola Virus Disease | P4 | Active | 40 | Open-label | rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO) |
| NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | P3 | Active | 412 | RCT, Open-label | disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin |
| NCT03682536 A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | Myelodysplastic Syndromes | P3 | Active | 363 | RCT, Open-label | Luspatercept, Epoetin alfa |
| NCT07159763 A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06) | Influenza | P3 | Recruiting | 10,000 | RCT, Double-blind | — |
| NCT01252953 REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | Atherosclerotic Cardiovascular Disease | P3 | Active | 30,449 | RCT, Double-blind | Anacetrapib, Placebo anacetrapib |
| NCT04624204 Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) | Small Cell Lung Cancer | P3 | Active | 672 | RCT, Double-blind | Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice |
| NCT07419295 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Bladder Cancer | P3 | Recruiting | 590 | RCT, Open-label | Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy |
| NCT04586231 A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) | Carcinoma, Renal Cell | P3 | Active | 747 | RCT, Open-label | Belzutifan, Lenvatinib, Cabozantinib |
| NCT04924608 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | Neurofibromatosis 1, Plexiform Neurofibroma (PN) | P3 | Active | 145 | RCT, Double-blind | Selumetinib |
| NCT06136585 Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial | Neuromuscular Blocks | P3 | Recruiting | 80 | RCT, Double-blind | 2 mg/kg sugammadex, 0.07 mg/kg neostigmine |
| NCT03725059 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | Breast Cancer | P3 | Active | 1,240 | RCT, Double-blind | Pembrolizumab (K), Placebo (P), Paclitaxel (X), Doxorubicin (A), Epirubicin (E), Cyclophosphamide (C), Endocrine therapy |
| NCT02811861 Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Renal Cell Carcinoma | P3 | Active | 1,069 | RCT, Open-label | Lenvatinib, Everolimus, Pembrolizumab, Sunitinib |
| NCT03765918 Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) | Head and Neck Neoplasms | P3 | Active | 714 | RCT, Open-label | Pembrolizumab 200 mg, Cisplatin 100 mg/m^2 |
| NCT05722015 A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | Metastatic Non-small Cell Lung Cancer | P3 | Active | 377 | RCT, Open-label | Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pembrolizumab, Filgrastim, Pegylated filgrastim |
| NCT06393374 Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Triple-Negative Breast Cancer | P3 | Recruiting | 1,530 | RCT, Open-label | Pembrolizumab, Sacituzumab tirumotecan, Capecitabine |
| NCT06052059 A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) | Ulcerative Colitis | P3 | Active | 1,109 | RCT, Double-blind | IV Tulisokibart, IV Placebo, SC Tulisokibart, SC Placebo |
| NCT03401788 A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | VHL - Von Hippel-Lindau Syndrome, VHL Gene Mutation | P2 | Active | 50 | Open-label | Belzutifan |
| NCT07225959 A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07) | Healthy Participants | P2 | Active | 400 | Open-label | — |
| NCT04262141 IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV) | Essential Thrombocythemia, Polycythemia Vera | P2 | Active | 4 | Open-label | IMG-7289 |
| NCT03634540 A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) | Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | P2 | Active | 118 | Open-label | Belzutifan, Cabozantinib |
| NCT04081220 Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2 | Thrombocythemia, Essential | P2 | Active | 9 | Open-label | IMG-7289 |
| NCT04143724 Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia | Beta-Thalassemia | P2 | Recruiting | 99 | Open-label | ACE-536 |
| NCT05270525 Effect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | Pulmonary Disease, Chronic Obstructive, COPD | P2 | Active | 70 | RCT, Double-blind | Ensifentrine, Placebo, LABA/LAMA |
| NCT05270668 Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) | Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease | P2 | Active | 154 | RCT, Double-blind | Tulisokibart, Placebo |
| NCT06559150 A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis | Non-cystic Fibrosis Bronchiectasis | P2 | Recruiting | 284 | RCT, Double-blind | Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution |
| NCT03162536 A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | Lymphoma, B-Cell, Small Lymphocytic Lymphoma | P1P2 | Active | 190 | Open-label | Nemtabrutinib |
| NCT06163430 A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL) | Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Chronic Myeloid Leukemia, Chronic Phase | P1P2 | Recruiting | 330 | RCT, Open-label | MK-4208 |
| NCT04471727 A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | Small-Cell Lung Cancer, Neuroendocrine Carcinoma | P1P2 | Active | 232 | Open-label | Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd) |
| NCT06100913 Immunology of Ebola Vaccine | Ebola Virus Disease | P2 | Active | 30 | Open-label | Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP) |
| NCT06809140 Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Muscle Invasive Bladder Urothelial Carcinoma | P2 | Recruiting | 75 | Open-label | Enfortumab vedotin, Pembrolizumab |
| NCT04145622 Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Advanced Solid Tumor, Malignant Solid Tumor | P1P2 | Active | 247 | Open-label | Ifinatamab deruxtecan (I-DXd) |
| NCT03414229 A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma | Sarcoma | P2 | Active | 30 | Open-label | Epacadostat, Pembrolizumab |
| NCT04869137 Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma | Merkel Cell Carcinoma, Neuroendocrine Carcinoma of the Skin | P2 | Active | 26 | Open-label | Lenvatinib Oral Product, Pembrolizumab |
| NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | Solid Tumor, Non-Small Cell Lung Cancer | P1P2 | Recruiting | 340 | RCT, Single-blind | INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2, Gemcitabine (1000 mg/m2) |
| NCT05366166 Pembrolizumab Plus Olaparib in LA-HNSCC | Squamous Cell Carcinoma of Head and Neck | P2 | Active | 45 | Open-label | Pembrolizumab, Olaparib, Cisplatin |
| NCT04920617 DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma | P2 | Recruiting | 102 | RCT, Open-label | DPX-Survivac, Pembrolizumab, CPA |
| NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] | HER2-positive Breast Cancer, Breast Cancer | P2 | Active | 138 | RCT, Open-label | Paclitaxel, Trastuzumab, Pertuzumab, Pembrolizumab |
| NCT05025813 Neoadjuvant Pembrolizumab in Cutaneous Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma of the Head and Neck, Head and Neck Cancer | P2 | Recruiting | 27 | Open-label | Pembrolizumab |
| NCT04471974 ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | P2 | Active | 61 | Open-label | BET Bromodomain Inhibitor ZEN-3694, Enzalutamide, Pembrolizumab |
| NCT07222488 A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003) | Bladder Cancer, Urinary Bladder Neoplasms | P1P2 | Recruiting | 45 | Open-label | MK-3120 |
| NCT05221645 Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | Diffuse Large B Cell Lymphoma | P2 | Active | 65 | RCT, Open-label | Pembrolizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide |
| NCT04980872 A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006) | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | P2 | Active | 60 | Open-label | Miransertib |
| NCT04956640 Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms | P1P2 | Active | 540 | Open-label | LY3537982, Pembrolizumab, Cetuximab, Pemetrexed, Cisplatin, Carboplatin |
| NCT05879146 Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study | Tumor | P2 | Recruiting | 40 | Open-label | Nirogacestat |
| NCT06979596 A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Malignant Neoplasm | P2 | Recruiting | 250 | RCT, Single-blind | Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate, Rescue Medications, Fulvestrant, Exemestane, Megestrol acetate/Medroxyprogesterone acetate, Tamoxifen, Letrozole |
| NCT07463183 A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) | Colitis Ulcerative, Ulcerative Colitis | P2 | Recruiting | 100 | RCT, Double-blind | MK-8690 |
| NCT03153202 Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P1P2 | Active | 23 | Open-label | Ibrutinib, Pembrolizumab |
| NCT04421560 Pembrolizumab, Ibrutinib and Rituximab in PCNSL | Primary Central Nervous System Lymphoma, Recurrent Cancer | P1P2 | Recruiting | 37 | Open-label | Ibrutinib, Pembrolizumab, Rituximab |
| NCT02858921 Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma | Melanoma | P2 | Active | 60 | RCT, Open-label | Dabrafenib, Trametinib, Pembrolizumab |
| NCT05147558 A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma | Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma | P2 | Active | 40 | Open-label | Pembrolizumab, Lenvatinib |
| NCT03485209 Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung | P2 | Active | 350 | Open-label | tisotumab vedotin, pembrolizumab, carboplatin, cisplatin |
| NCT06340711 Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma | Esophageal Adenocarcinoma, Gastric Adenocarcinoma | P2 | Recruiting | 27 | Open-label | OBP-301, Pembrolizumab |
| NCT06976944 Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer | Recurrent Triple-Negative Breast Cancer | P2 | Recruiting | 24 | RCT, Open-label | Pembrolizumab, Paclitaxel, Bevacizumab |
| NCT03989089 Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation | HER2-Negative Breast Cancer | P2 | Active | 44 | Open-label | Pembrolizumab |
| NCT06307431 A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Renal Cell Carcinoma | P2 | Active | 272 | RCT, Double-blind | Intismeran autogene, Pembrolizumab, Placebo |
| NCT06956235 Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) | Hidradenitis Suppurativa | P2 | Active | 149 | RCT, Double-blind | Tulisokibart, Placebo |
| NCT02998268 Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma | Esophageal Adenocarcinoma | P2 | Active | 42 | RCT, Open-label | Pembrolizumab, Taxol, Carboplatin |
| NCT03618550 Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma | P2 | Recruiting | 257 | Open-label | pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin |
| NCT07221474 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) | Squamous Non-small Cell Lung Cancer | P2 | Recruiting | 180 | RCT, Double-blind | Intismeran Autogene, Pembrolizumab, Carboplatin, Paclitaxel, Nab-paclitaxel |
| NCT03504163 Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] | Bladder Cancer | P2 | Active | 45 | Open-label | Pembrolizumab (MK-3475), Bacillus Calmette-Guérin (BCG) |
| NCT05458297 A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P2 | Active | 189 | RCT, Open-label | Zilovertamab vedotin, Nemtabrutinib |
| NCT05394103 Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Advanced Cancer, Metastatic Cancer | P1P2 | Recruiting | 130 | Open-label | Q901, KEYTRUDA® (pembrolizumab) |
| NCT04438213 Ertugliflozin in Chronic Heart Failure | Heart Failure | P2 | Recruiting | 60 | RCT, Double-blind | Ertugliflozin, Metolazone, Placebo |
| NCT05597306 Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | P1 | Recruiting | 18 | Open-label | Bomedemstat, Venetoclax |
| NCT02974738 A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | Advanced Solid Tumors, Solid Tumor | P1 | Active | 120 | Open-label | Belzutifan |
| NCT02293980 A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | ccRCC, RCC | P1 | Active | 110 | Open-label | MK-3795, Nivolumab, Cabozantinib, Bezlutifan |
| NCT07300085 A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007) | Healthy Participants | P1 | Recruiting | 710 | RCT, Double-blind | Fluzone® High-Dose (HD) influenza vaccine |
| NCT04184050 Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) | Multiple Myeloma in Relapse, Multiple Myeloma | P1 | Active | 100 | Open-label | MK-4002 |
| NCT03260491 U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | P1 | Active | 312 | Open-label | HER3-DXd (FL-DP), HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) |
| NCT07712575 A Study of V132 in Healthy Older Participants (V132-001) | Healthy | P1 | Recruiting | 280 | RCT, Double-blind | V132 Formulation 1, V132 Formulation 2, V132 Formulation 3, PREVNAR 20™, CAPVAXIVE™ |
| NCT02560636 Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer | Invasive Bladder Cancer | P1 | Active | 34 | Open-label | Pembrolizumab |
| NCT06540391 A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients | Melanoma | P1 | Active | 41 | RCT, Open-label | MB097, Pembrolizumab, Vancomycin |
| NCT00404989 Antiretroviral Pregnancy Registry (APR): Multi-sponsor Registry to Detect Any Major Teratogenic Effect Involving Any of the Registry Drugs When Administered to Pregnant People. | HIV Infections, Hepatitis B | Recruiting | 24,258 | — | — | |
| NCT01731353 FungiScope - A Global Emerging Fungal Infection Registry | Invasive Fungal Disease | Recruiting | 1,000 | — | — | |
| NCT02438631 Placental Passage and Disposition of Drugs: A Physiology-based Approach | Pregnancy | Recruiting | 2,000 | — | — | |
| NCT06036810 Spanish Decision Tool for Ovarian Cancer Maintenance Therapy | Ovarian Cancer | N/A | Recruiting | 70 | Open-label | — |
| NCT06681077 A Community Health Education Intervention for Increasing Community-driven Actions to Reduce the Cancer Burden in Western New York | Healthy | N/A | Recruiting | 500 | RCT, Double-blind | — |
| NCT05467917 ARMOR-Household: Characterizing Transmission of COVID-19 in Households of SARS-CoV-2 Index Cases | COVID-19, Households | Active | 374 | — | — | |
| NCT00414115 National Active Surveillance Network and Pharmacogenomics of Adverse Drug Reactions in Children | Adverse Drug Reaction (ADR) | Recruiting | 7,000 | — | — | |
| NCT05376891 Met Non Small Cell Cancer Registry (MOMENT) | Cancer | Recruiting | 700 | — | — | |
| NCT01818141 Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin | Clostridium Difficile Infection | P4 | Completed | 34 | RCT, Open-label | Vancomycin, Fidaxomicin |
| NCT01775397 A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System | Clostridium Difficile | P4 | Terminated | 12 | RCT, Double-blind | Fidaxomicin, Vancomycin, Placebo |
| NCT00572260 A Pilot Study of Daptomycin for Antimicrobial Prophylaxis | Antimicrobial Prophylaxis | P4 | Terminated | 11 | Open-label | daptomycin 6 mg/kg IV |
| NCT00638157 Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) | Infective Endocarditis | P4 | Terminated | 24 | RCT, Double-blind | daptomycin, daptomycin and gentamicin |
| NCT01175707 Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting | Complicated Skin or Skin Structure Infection | P4 | Terminated | 80 | RCT, Open-label | Daptomycin, Vancomycin |
| NCT00102947 Daptomycin in the Treatment of Patients With Renal Insufficiency and Complicated Skin and Skin Structure Infections | Soft Tissue Infections | P4 | Terminated | 72 | RCT, Open-label | daptomycin (up to 14 days) |
| NCT00295178 Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas | Cellulitis | P4 | Completed | 80 | RCT, Single-blind | Daptomycin, Vancomycin |
| NCT00651131 Cubicin(R) for Complicated Post-surgical Wound Infections | Wound Infections | P4 | Terminated | 69 | RCT, Open-label | daptomycin |
| NCT01133600 Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens | Diabetic Foot | P4 | Terminated | 6 | RCT, Open-label | Cubicin, Vancomycin |
| NCT00711802 Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections | Skin Diseases, Infectious | P4 | Completed | 396 | RCT, Single-blind | Daptomycin, Standard of Care (SOC) |
| NCT00663403 Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD) | Critically Ill, Hemodialysis | P4 | Completed | 8 | Open-label | Daptomycin |
| NCT02355938 Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury | Clostridium Difficile, Spinal Cord Injury | P4 | Terminated | 12 | RCT, Double-blind | Fidaxomicin 200 mg, Placebo, Vancomycin |
| NCT01728376 Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005) | Bacteremia | P4 | Completed | 82 | RCT, Open-label | Daptomycin, Comparator |
| NCT01419184 Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA | Staphylococcal Skin Infections | P4 | Completed | 250 | RCT, Open-label | Daptomycin, Vancomycin |
| NCT01287832 Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) | Bacteremia | P4 | Terminated | 11 | RCT, Open-label | Vancomycin, Daptomycin |
| NCT00708201 A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy | Postoperative Ileus | P4 | Completed | 280 | RCT, Double-blind | Alvimopan, Placebo |
| NCT02421120 Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients | Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation | P4 | Completed | 21 | Open-label | Ceftolozane/Tazobactam |
| NCT01104662 Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment | Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia | P4 | Terminated | 92 | RCT, Single-blind | Vancomycin, Daptomycin, Semi-Synthetic Penicillin |
| NCT01196169 Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty | Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus | P4 | Terminated | 28 | RCT, Open-label | Daptomycin, Vancomycin |
| NCT01142466 A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone | Multiple Sclerosis, Relapsing-Remitting | P4 | Completed | 30 | RCT, Open-label | Interferon beta-1a (Rebif) |
| NCT00629941 Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis | Blepharitis | P4 | Completed | 25 | Open-label | AzaSite® |
| NCT00833027 ALPHA Sitagliptin Add on to Metformin (0431-103) | Diabetes Mellitus | P4 | Completed | 608 | Open-label | sitagliptin phosphate |
| NCT05061654 CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients | Neutropenia, Febrile, Hematologic Cancer | P4 | Withdrawn | — | Open-label | Ceftolozane-tazobactam IV |
| NCT03170661 Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions. | Surgical Conditions | P4 | Completed | 98 | RCT, Double-blind | Deep neuromuscular block |
| NCT07706166 Letermovir for R+ Study | Kidney Transplant, Liver Transplant | P4 | Not Yet Recruiting | 146 | Open-label | Letermovir |
| NCT03002506 Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns | Burns, Pharmacokinetics | P4 | Terminated | 6 | Open-label | Ceftolozane/tazobactam |
| NCT02704754 Suvorexant and Trauma Related Insomnia | Insomnia, Posttraumatic Stress Disorder | P4 | Completed | 41 | RCT, Double-blind | suvorexant |
| NCT00202839 Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED) | Hepatitis C, Chronic | P4 | Completed | 160 | RCT, Open-label | PegIntron (peginterferon alfa-2b; SCH 54031), PegIntron (peginterferon alfa-2b; SCH 54031), Ribavirin, Ribavirin |
| NCT00656539 Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis | Blepharitis | P4 | Completed | 20 | RCT, Open-label | AzaSite® |
| NCT00721240 Investigation to Identify Predictors of Response to a Treatment With Montelukast | Asthma | P4 | Completed | 50 | Open-label | montelukast |
| NCT03111108 Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096) | Hepatitis C Virus (HCV) Infection | P4 | Completed | 117 | RCT, Open-label | EBR/GZR (50 mg/100 mg) FDC |
| NCT01549041 Once-Daily Asenapine for Schizophrenia | Schizophrenia | P4 | Completed | 30 | RCT, Open-label | Asenapine 10 mg daily in the evening, Asenapine 5 mg twice daily |
| NCT00157690 Study of Alendronate to Prevent and Treat Osteoporosis in Cystic Fibrosis Patients | Cystic Fibrosis, Osteoporosis | P4 | Completed | 56 | RCT, Double-blind | Alendronate, Placebo |
| NCT00708539 A Prospective Randomized Multicentre Study to Compare Crinone 8% Once Daily Versus Other Vaginal Progesterone. | IVF - Luteal Phase Support After Embryo Transfer | P4 | Unknown | 2,686 | RCT, Single-blind | progesterone, Progesterone |
| NCT00575380 Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery | Bacterial Infections, Eye Infections | P4 | Completed | 116 | RCT, Open-label | AzaSite Eye Drops, Vigamox Eye Drops |
| NCT02484651 Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade? | Neuromuscular Block | P4 | Completed | 70 | RCT, Open-label | Sugammadex, Rocuronium |
| NCT02342418 Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults | Obesity | P4 | Completed | 19 | Open-label | Tedizolid phosphate |
| NCT00781287 Raltegravir (Isentress/MK-0518) and HIV-1 Infected CD4 Cells During Acute/Early HIV-1 | Human Immunodeficiency Virus | P4 | Terminated | 10 | RCT, Open-label | 3-drug anti-HIV therapy, Raltegravir |
| NCT01926015 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) | Rotavirus Disease | P4 | Completed | 192 | RCT, Open-label | RotaTeq™ (V260), DTP-IPV |
| NCT04334551 HIV Switch Trial in Experienced Patients With Multiple Class Resistance Including NNRTI Resistance | HIV Infections | P4 | Unknown | 40 | Open-label | Doravirine |
| NCT01025765 The Effects of Oral Hypoglycemic Agents on Chronic Hepatitis C Patients Receiving Peg-Intron Plus Ribavirin | Chronic Hepatitis C | P4 | Unknown | 80 | RCT, Open-label | Pioglitazone, Acarbose, Metformin |
| NCT01667107 A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105) | Fungal Infection | P4 | Terminated | 26 | Open-label | Posaconazole, Calogen® |
| NCT01148901 Effectiveness and Safety of Early Treatment With Infliximab for Hip Arthritis Associated With Ankylosing Spondylitis (AS) (P06451) | Ankylosing Spondylitis | P4 | Withdrawn | — | Open-label | Infliximab |
| NCT00520234 Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU) | Invasive Candidiasis | P4 | Completed | 222 | RCT, Double-blind | Caspofungin, Normal Saline |
| NCT03381859 Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4 | Hepatitis C Virus Infection, Response to Therapy of | P4 | Withdrawn | — | Open-label | Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] |
| NCT02406443 The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion | Type 2 Diabetes | P4 | Completed | 36 | RCT, Double-blind | Sitaglitpin |
| NCT01727271 A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384) | Hepatitis B | P4 | Withdrawn | — | RCT, Open-label | Tenofovir, Pegylated interferon alpha-2b |
| NCT01027806 Effect of Montelukast Therapy in Obstructive Sleep Apnea(OSA) Children | Obstructive Sleep Apnea | P4 | Terminated | 64 | RCT, Double-blind | Montelukast |
| NCT05289271 Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016) | Vaccines, Combined, Hexavalent Vaccine | P4 | Completed | 168 | Open-label | Vaxelis™ |
| NCT01871532 Low-dose Gonal-f® in Ovulation Induction | Infertility, Monofollicular Development | P4 | Terminated | 24 | RCT, Open-label | Gonal-f® |
| NCT00265252 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis | Non-Traumatic Osteonecrosis | P4 | Unknown | 60 | RCT, Double-blind | Alendronate |
| NCT00466401 Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation | Hypercholesterolemia | P4 | Completed | 20 | Open-label | Simvastatin, Ezetimibe |
| NCT00993187 Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) | Type 2 Diabetes Mellitus | P4 | Completed | 292 | RCT, Double-blind | Sitagliptin/Metformin FDC, Comparator: Glimepiride, Matching placebo to Sitagliptin/Metformin FDC, Matching placebo to glimepiride |
| NCT00650663 Ezetimibe Plus Simvastatin Versus Simvastatin Alone in African-American Subjects With Primary Hypercholesterolemia (P03377) | Hypercholesterolemia, Atherosclerosis | P4 | Completed | 247 | RCT, Double-blind | Ezetimibe + Simvastatin, Simvastatin |
| NCT00157898 A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED) | Complicated Intra-abdominal Infection | P4 | Completed | 134 | RCT, Open-label | MK0826; ertapenem sodium, Comparator: ceftriaxone + metronidazole |
| NCT00119015 The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis | Rhinitis, Allergic, Perennial | P4 | Terminated | 102 | RCT, Double-blind | Placebo, Montelukast, Fluticasone propionate |
| NCT01364090 A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 | Hepatitis C, Chronic | P4 | Completed | 93 | Open-label | Pegylated interferon alfa 2b, Ribavirin |
| NCT01173510 A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells | HIV Infections, Acquired Immune Deficiency Syndrome | P4 | Withdrawn | — | RCT, Open-label | Raltegravir plus Truvada, Atripla |
| NCT01364298 Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in Diabetic Peripheral Neuropathy Pain Management | Diabetic Peripheral Neuropathic Pain | P4 | Completed | 353 | RCT, Open-label | Gabapentin/B-complex, Pregabalin |
| NCT03420300 EBR/GZR for HCV-1b Patients Receiving Hemodialysis | Hepatitis C | P4 | Completed | 40 | Open-label | EBR/GZR |
| NCT00939874 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density | HIV, Osteopenia | P4 | Completed | 52 | Open-label | Raltegravir |
| NCT00686725 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) | Glioblastoma | P4 | Completed | 99 | RCT, Open-label | Temozolomide |
| NCT01419249 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study | Idiopathic Growth Hormone Deficiency, Turner Syndrome | P4 | Completed | 458 | Open-label | — |
| NCT00910689 Drug and Non-Drug Treatment Of Severe Migraine | Migraine Headache | P4 | Completed | 232 | RCT, Double-blind | Propranolol or nadolol, Placebo control, Optimal Acute Therapy |
| NCT03351608 Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089) | Neuromuscular Blockade | P4 | Completed | 288 | RCT, Double-blind | Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine |
| NCT00348855 Study to Improve Quality of Care and Patient Health in the Field of Cardiovascular Risk Factors in General Practice | High Risk Hypertensive Patients | P4 | Completed | 1,836 | RCT, Single-blind | — |
| NCT00934713 The Effect of Montelukast Treatment in Wheezy Infants | Lung Disease, Obstructive, Signs and Symptoms, Respiratory | P4 | Completed | 112 | RCT, Double-blind | montelukast |
| NCT03520959 A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) | Synovial Sarcoma, Cancer | P3 | Terminated | 1 | RCT, Double-blind | LV305, G305 |
| NCT00540072 Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia Due to S. Pneumoniae | Pneumonia, Bacterial | P3 | Completed | — | RCT, Double-blind | daptomycin |
| NCT00468728 PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) | Clostridium Infections, Diarrhea | P3 | Completed | 535 | RCT, Double-blind | PAR-101/OPT-80, Vancomycin |
| NCT00241722 Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Bowel Dysfunction, Constipation | P3 | Completed | 805 | RCT, Double-blind | Alvimopan, Placebo |
| NCT00701636 Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery | Late Effects of Surgery, Staphylococcus Aureus | P3 | Completed | 30 | Open-label | daptomycin |
| NCT03667690 Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis | Candidemia, Mycoses | P3 | Completed | 199 | RCT, Double-blind | Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo |
| NCT04896008 A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH) | Pulmonary Arterial Hypertension | P3 | Completed | 173 | RCT, Double-blind | Sotatercept |
| NCT04576988 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) | Pulmonary Arterial Hypertension | P3 | Completed | 324 | RCT, Double-blind | Sotatercept, Placebo, Background PAH Therapy |
| NCT02631070 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | Myelodysplastic Syndromes | P3 | Completed | 229 | RCT, Double-blind | Luspatercept |
| NCT00055198 Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria | Gram-Positive Bacterial Infections | P3 | Terminated | 75 | Open-label | daptomycin |
| NCT00388479 Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/ Postoperative Ileus | Ileus | P3 | Completed | 666 | RCT, Double-blind | Alvimopan |
| NCT01216241 Daptomycin Versus Placebo in Patients With Neutropenia and Fever | Febrile Neutropenia | P3 | Terminated | 36 | RCT, Double-blind | Daptomycin, Daptomycin |
| NCT01691248 Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) | Clostridium Difficile-Associated Diarrhea (CDAD) | P3 | Completed | 611 | RCT, Double-blind | fidaxomicin, Placebo |
| NCT00443690 Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy | Heart Failure, Congestive | P3 | Completed | 480 | RCT, Double-blind | rolofylline, Comparator: Placebo (unspecified) |
| NCT01901328 Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Opioid-Induced Constipation | P3 | Terminated | 49 | RCT, Double-blind | CB-5945, Placebo |
| NCT01345929 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis | Complicated Urinary Tract Infection, Pyelonephritis | P3 | Completed | 558 | RCT, Double-blind | CXA-201, Levofloxacin |
| NCT04095858 Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) | Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | P3 | Terminated | 11 | RCT, Double-blind | Efprezimod alfa, Placebo, Methotrexate, Tacrolimus |
| NCT00314951 Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018) | Clostridium Infections, Diarrhea | P3 | Completed | 629 | RCT, Double-blind | Fidaxomicin, Vancomycin, Matching Placebo to Fidaxomicin |
| NCT01170221 TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections. | Skin and Subcutaneous Tissue Bacterial Infections | P3 | Completed | 667 | RCT, Double-blind | TR-701 FA, Linezolid |
| NCT00256932 Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Bowel Dysfunction, Constipation | P3 | Completed | 518 | RCT, Double-blind | alvimopan, Placebo |
| NCT04317040 Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007) | Coronavirus Disease 2019 (COVID-19) | P3 | Completed | 234 | RCT, Double-blind | Efprezimod alfa, Placebo |
| NCT01853982 Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia | Ventilator-Associated Pneumonia (VAP) | P3 | Terminated | 4 | RCT, Open-label | Ceftolozane/Tazobactam, Piperacillin/Tazobactam |
| NCT00093067 Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus | Bacterial Endocarditis, Bacteremia | P3 | Completed | — | RCT, Open-label | daptomycin |
| NCT02604433 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia | Erythrocyte Transfusion, Beta-Thalassemia | P3 | Completed | 336 | RCT, Double-blind | Luspatercept |
| NCT02019420 Tedizolid Phosphate (TR-701 FA, MK-1986) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002) | Pneumonia | P3 | Completed | 726 | RCT, Double-blind | Tedizolid phosphate, Linezolid |
| NCT00388258 Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | Ileus | P3 | Completed | 451 | RCT, Double-blind | Alvimopan |
| NCT01755767 Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy | Hepatocellular Carcinoma | P3 | Completed | 383 | RCT, Double-blind | Tivantinib, Placebo |
| NCT02276482 Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012) | Skin Diseases, Infectious, Skin Diseases, Bacterial | P3 | Completed | 120 | RCT, Single-blind | Tedizolid Phophate, Antibiotic comparator, Aztreonam, Metronidazole |
| NCT01597505 Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005) | Clostridium Difficile Infection | P3 | Completed | 606 | RCT, Double-blind | Surotomycin, Vancomycin, Placebo |
| NCT04535986 A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Chronic Obstructive Pulmonary Disease | P3 | Completed | 763 | RCT, Double-blind | Ensifentrine, Placebo |
| NCT01445678 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections | Complicated Intra-abdominal Infection | P3 | Completed | 494 | RCT, Double-blind | CXA-201 and metronidazole, Meropenem |
| NCT00205842 Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | Ileus | P3 | Completed | 660 | RCT, Double-blind | alvimopan |
| NCT06460493 Effect of Ensifentrine Treatment on CAT Score | COPD | P3 | Completed | 20 | Open-label | Ensifentrine 3 mg twice daily |
| NCT02070757 Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008) | Healthcare-Associated Pneumonia, Ventilator-Associated Pneumonia | P3 | Completed | 726 | RCT, Double-blind | Ceftolozane/tazobactam, Meropenem |
| NCT00354458 PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | Heart Failure, Congestive | P3 | Completed | 1,102 | RCT, Double-blind | rolofylline, Comparator: Placebo (unspecified) |
| NCT01421511 TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections | Skin and Subcutaneous Tissue Bacterial Infections | P3 | Completed | 666 | RCT, Double-blind | TR-701 FA, Linezolid |
| NCT01922011 Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006) | Acute Hematogenous Osteomyelitis | P3 | Completed | 149 | RCT, Double-blind | Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent) |
| NCT04542057 A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | Chronic Obstructive Pulmonary Disease | P3 | Completed | 790 | RCT, Double-blind | Ensifentrine, Placebo |
| NCT01696643 Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Opioid-Induced Constipation | P3 | Terminated | 1,407 | RCT, Double-blind | CB-5945, Placebo |
| NCT00388401 Study of Alvimopan for the Management of Opioid-induced Postoperative Bowel Dysfunction/Postoperative Ileus | Ileus | P3 | Completed | 510 | RCT, Double-blind | Alvimopan |
| NCT00328692 PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal Function | Heart Failure, Congestive | P3 | Completed | 932 | RCT, Double-blind | rolofylline, Comparator: Placebo (unspecified) |
| NCT01704651 Accelerating Gastrointestinal Recovery | Ovarian Cancer, Fallopian Tube Cancer | P3 | Completed | 146 | RCT, Double-blind | Alvimopan, Placebo |
| NCT00259922 Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | Bowel Dysfunction, Constipation | P3 | Completed | 485 | RCT, Double-blind | Placebo, Alvimopan, Alviompan |
| NCT00538694 Comparative Study of Cidecin™ (Daptomycin) to Rocephin® (Ceftriaxone) in the Treatment of Moderate to Severe Community-Acquired Acute Bacterial Pneumonia | Pneumonia, Bacterial | P3 | Completed | — | RCT, Double-blind | daptomycin |
| NCT00448422 Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers | Acute Bacterial Gastroenteritis | P3 | Completed | 268 | RCT, Double-blind | prulifloxacin |
| NCT04811092 Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13) | Pulmonary Arterial Hypertension | P3 | Terminated | 321 | RCT, Double-blind | Sotatercept |
| NCT01901341 The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Opioid-Induced Constipation | P3 | Terminated | 44 | RCT, Double-blind | CB-5945, Placebo |
| NCT01598311 A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006) | Clostridium Difficile Infection | P3 | Completed | 608 | RCT, Double-blind | CB-183,315, Vancomycin, Placebo |
| NCT01901302 Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation | Opioid-Induced Constipation | P3 | Terminated | 61 | RCT, Double-blind | CB-5945, Placebo |
| NCT01244191 Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | Non Squamous, Non-small-cell Lung Cancer | P3 | Terminated | 1,048 | RCT, Double-blind | Tivantinib, Placebo, Erlotinib |
| NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) | Colorectal Cancer | P3 | Completed | 441 | RCT, Open-label | favezelimab/pembrolizumab, regorafenib, TAS-102 |
| NCT02577003 Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843) | Type 2 Diabetes Mellitus | P3 | Completed | 143 | RCT, Double-blind | Ipragliflozin, Placebo, Sitagliptin |
| NCT00876317 Etoricoxib in Acute Soft Tissue Rheumatism Affecting the Shoulder | Soft Tissue Injuries of the Shoulder, Tenosynovitis and Bursitis Affecting the Shoulder | P3 | Terminated | 45 | RCT, Double-blind | Etoricoxib 60 mg, Etoricoxib 90 mg |
| NCT00375388 The HOME Trial: Hyperinsulinaemia: the Outcome of Its Metabolic Effects, a Randomized Controlled Trial | Type 2 Diabetes Mellitus | P3 | Completed | 400 | RCT, Double-blind | Metformin on top of intensive insulin therapy |
| NCT00988520 Study of Efficacy, Pharmacokinetics and Safety of Continuous Intravenous Infusion of Org 9426 (Study P05977) | Anesthesia | P3 | Completed | 38 | RCT, Open-label | Rocuronium bromide, Rocuronium bromide, Rocuronium bromide, Sevoflurane, Propofol |
| NCT03361865 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) | UC (Urothelial Cancer) | P3 | Completed | 93 | RCT, Open-label | Pembrolizumab, Epacadostat, Placebo |
| NCT00750919 Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) | Sleep Initiation and Maintenance Disorders, Mental Disorders | P3 | Terminated | 184 | Open-label | esmirtazapine |
| NCT03950622 Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE) | Pneumococcal Infections | P3 | Completed | 1,205 | RCT, Double-blind | V114, Prevnar 13® |
| NCT00048607 Treatment of Patients With Major Depressive Disorder With MK0869 (0869-062)(COMPLETED) | Major Depressive Disorder | P3 | Completed | 600 | RCT, Double-blind | aprepitant, Comparator: paroxetine HCL, Comparator: Placebo (Unspecified) |
| NCT03284866 HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV | AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia | P3 | Completed | 535 | RCT, Double-blind | Recombinant Human Papillomavirus Nonavalent Vaccine |
| NCT00541775 Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801) | Type 2 Diabetes Mellitus | P3 | Completed | 273 | RCT, Double-blind | Sitagliptin, Comparator: Rosiglitazone, Comparator: Placebo, Comparator: Metformin |
| NCT00124072 Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine | Cardiovascular Disease | P3 | Completed | 12,064 | RCT, Double-blind | Simvastatin 20 mg daily, Simvastatin 80 mg daily, Placebo |
| NCT05569954 Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10) | Pneumococcal Disease | P3 | Completed | 1,484 | RCT, Double-blind | V116, PPSV23 |
| NCT01995721 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children | Recurrent Respiratory Papillomatosis | P3 | Unknown | 20 | Open-label | 4-valent HPV vaccine |
| NCT00358670 Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563) | Psoriasis | P3 | Terminated | 441 | RCT, Open-label | infliximab, infliximab |
| NCT00035295 Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061) | Major Depressive Disorder | P3 | Completed | 584 | RCT, Double-blind | MK0869, aprepitant, Comparator: placebo |
| NCT00292266 A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS) | Multiple Sclerosis, Relapsing-Remitting | P3 | Completed | 677 | RCT, Open-label | Rebif®, Avonex® |
| NCT02137772 Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) | Prevention of CMV Infection or Disease | P3 | Completed | 570 | RCT, Double-blind | Letermovir, Placebo |
| NCT00322231 A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014) | Herpes Zoster | P3 | Completed | 101 | RCT, Double-blind | zoster vaccine live (ZOSTAVAX™), Comparator: Placebo |
| NCT00449930 Sitagliptin Comparative Study in Patients With Type 2 Diabetes (0431-049) | Type 2 Diabetes Mellitus | P3 | Completed | 1,050 | RCT, Double-blind | sitagliptin phosphate, Comparator: metformin hydrochloride |
| NCT00564460 On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP) | Benign Prostatic Hyperplasia | P3 | Withdrawn | — | RCT, Double-blind | Finasteride, Placebo |
| NCT02625623 Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) | Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line | P3 | Completed | 371 | RCT, Open-label | Avelumab, Irinotecan, Paclitaxel |
| NCT02576574 Avelumab in First-line NSCLC (JAVELIN Lung 100) | First Line Non-Small Cell Lung Cancer | P3 | Completed | 1,214 | RCT, Open-label | Avelumab, Pemetrexed, Paclitaxel, Gemcitabine, Gemcitabine, Carboplatin, Cisplatin, Carboplatin, Avelumab Weekly |
| NCT00535288 Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013) | Postmenopausal Symptoms, Menopause | P3 | Completed | 946 | RCT, Double-blind | Esmirtazapine, Placebo |
| NCT03260894 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) | Renal Cell Carcinoma (RCC) | P3 | Completed | 129 | RCT, Open-label | Pembrolizumab, Epacadostat, Sunitinib, Pazopanib |
| NCT01060488 Comparative Validation of the Growth Hormone Releasing Hormone and Arginine Test for the Diagnosis of Adult Growth Hormone Deficiency | Growth Hormone Deficiency | P3 | Completed | 69 | RCT, Open-label | — |
| NCT00943722 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002) | Cervical Cancers, Vulvar Cancer | P3 | Completed | 3,074 | RCT, Open-label | V503 |
| NCT00372060 MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED) | Type 2 Diabetes Mellitus | P3 | Completed | 134 | RCT, Double-blind | sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone, Comparator: placebo (unspecified) |
| NCT00474370 Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED) | HIV Infections, Acquired Immunodeficiency Syndrome | P3 | Completed | 400 | RCT, Double-blind | Vicriviroc, Placebo |
| NCT01860729 A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022) | Hypercholesterolemia | P3 | Completed | 589 | RCT, Double-blind | Anacetrapib, Placebo |
| NCT00535496 Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698) | Neuromuscular Blockade | P3 | Completed | 91 | RCT, Open-label | sugammadex |
| NCT01114425 Safety Study of Isentress® + Truvada® in Post-exposure Treatment of HIV Infection | HIV Infections | P3 | Completed | 149 | Open-label | raltegravir (Isentress), Truvada® |
| NCT00092313 A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-182) | Postoperative Pain | P3 | Completed | 271 | RCT, Double-blind | MK0966, rofecoxib, Comparator: oxycodone and acetaminophen |
| NCT01697592 Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015) | Type 2 Diabetes Mellitus | P3 | Completed | 585 | RCT, Double-blind | Omarigliptin, Matching placebo to omarigliptin |
| NCT00092859 A 2-Year Study of an Investigational Drug in Obese Patients (0557-011) | Obesity | P3 | Completed | 1,500 | RCT, Double-blind | MK0557 |
| NCT00650689 Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396) | Hypercholesterolemia, Atherosclerosis | P3 | Completed | 122 | RCT, Double-blind | Ezetimibe + Atorvastatin, Atorvastatin |
| NCT02819518 Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Triple Negative Breast Cancer (TNBC) | P3 | Completed | 882 | RCT, Double-blind | Pembrolizumab, Nab-paclitaxel, Paclitaxel, Gemcitabine, Carboplatin, Normale Saline Solution |
| NCT00269217 Lipid Efficacy Study (0524B-022)(COMPLETED) | Primary Hypercholesterolemia, Mixed Hyperlipidemia | P3 | Completed | 1,400 | RCT, Double-blind | niacin (+) laropiprant (+) simvastatin, Comparator: niacin (+) laropiprant, Comparator: simvastatin |
| NCT00473889 A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | Stage IIIB or IV Non-Small Cell Lung Cancer | P2P3 | Terminated | 253 | RCT, Double-blind | vorinostat, Comparator: paclitaxel, Comparator: carboplatin, Comparator: placebo |
| NCT01977794 Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension | Hypertension | P3 | Completed | 200 | RCT, Open-label | Bisoprolol/Amlodipine (Bisoprolol failed group), Bisoprolol/Amlodipine (Amlodipine failed group) |
| NCT02563002 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | Colorectal Carcinoma | P3 | Completed | 307 | RCT, Open-label | mFOLFOX6, FOLFIRI, Pembrolizumab, Bevacizumab, Cetuximab |
| NCT03884101 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) | Endometrial Neoplasms | P3 | Completed | 842 | RCT, Open-label | Lenvatinib, Pembrolizumab, Paclitaxel, Carboplatin |
| NCT01014013 Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055) | Urinary Tract Infection | P3 | Completed | 271 | RCT, Double-blind | ertapenem sodium (MK0826), Comparator: ceftriaxone sodium |
| NCT01033760 Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) | HIV-1 Infections | P3 | Completed | 90 | RCT, Open-label | raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine, darunavir; ritonavir; emtricitabine/tenofovir |
| NCT00092079 A Study of MK0217A and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227) | Osteoporosis, Vitamin D Deficiency | P3 | Completed | 652 | RCT, Double-blind | MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks |
| NCT00283686 HALT Progression of Polycystic Kidney Disease Study A | Kidney, Polycystic | P3 | Completed | 558 | RCT, Double-blind | Lisinopril, Telmisartan, Placebo |
| NCT00380367 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029) | Papillomavirus Infections | P3 | Completed | 110 | Open-label | Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine |
| NCT02252016 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065) | Hepatitis C | P3 | Completed | 159 | RCT, Double-blind | Grazoprevir + Elbasvir, Placebo |
| NCT00092430 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) | Measles, Mumps | P3 | Completed | 1,200 | RCT, Double-blind | V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks |
| NCT01590771 A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253) | Type 2 Diabetes Mellitus | P3 | Completed | 498 | RCT, Double-blind | Sitagliptin, Placebo, Gliclazide, Glimepiride, Metformin |
| NCT01340937 A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) | Bacterial Infections, Virus Diseases | P3 | Completed | 2,808 | RCT, Double-blind | V419, PENTACEL™, Prevnar 13™, RotaTeq™, Recombivax HB vaccine |
| NCT01047345 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) | Cervical Cancers, Vulvar Cancers | P3 | Completed | 924 | RCT, Double-blind | V503, Placebo to V503 |
| NCT03222167 Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b | Chronic Hepatitis C Genotype 1B, Metabolic Syndrome | P3 | Unknown | 60 | Open-label | Elbasvir/ Grazoprevir 50/100 mg fixed dose combination |
| NCT03843632 Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058) | Varicella | P3 | Completed | 150 | Open-label | VARIVAX™ |
| NCT02180165 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) | Aspergillosis | P3 | Completed | 116 | RCT, Open-label | Posaconazole, Voriconazole |
| NCT00681590 Safety of Vitamin D Supplementation in Older Persons | Vitamin D Deficiency | P3 | Completed | 105 | RCT, Double-blind | — |
| NCT00732641 Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7) | Multiple Myeloma | P3 | Completed | 244 | RCT, Open-label | Peginterferon |
| NCT01293643 A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis (P08077) | Vaginosis, Bacterial, Candidiasis, Vulvovaginal | P3 | Completed | 99 | RCT, Open-label | 100 mg clindamycin /800 mg ketoconazole vaginal ovule, 100 mg tetracycline hydrochloride /50 mg amphotericin B cream |
| NCT01462266 Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260) | Type 2 Diabetes Mellitus | P3 | Completed | 660 | RCT, Double-blind | Sitagliptin, Comparator: Placebo, Insulin Glargine, Metformin |
| NCT04384107 Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) | Pneumococcal Infections | P3 | Completed | 694 | RCT, Double-blind | V114, PCV13 |
| NCT00811928 Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED) | Leukopenia | P3 | Completed | 252 | RCT, Open-label | Posaconazole, Fluconazole |
| NCT02256436 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) | Urothelial Cancer | P3 | Completed | 542 | RCT, Open-label | pembrolizumab, paclitaxel, vinflunine, docetaxel |
| NCT00521924 Induction of Remission in RA Patients at Low Disease Activity by Additional Infliximab Therapy (Study P04644AM1) (TERMINATED) | Rheumatoid Arthritis | P3 | Terminated | 8 | RCT, Open-label | infliximab, DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89. |
| NCT04233216 Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019) | HIV-1 Infection | P3 | Completed | 35 | RCT, Double-blind | ISL, DOR, DOR/ISL, Placebo to ISL, Placebo to DOR |
| NCT03537274 Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016) | Hepatitis C | P2P3 | Completed | 1,224 | RCT, Double-blind | PEG-Intron, Interferon Alfa-2B |
| NCT00210080 A Study to Diagnose Lung Cancer by Sputum Cytology (01-312) | Lung Cancer | P3 | Completed | 700 | RCT, Double-blind | Uridine 5'-Triphosphate (UTP) Solution for Inhalation |
| NCT00813709 Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX) | Multiple Sclerosis, Clinically Isolated Syndrome | P3 | Completed | 402 | RCT, Double-blind | RNF, RNF, RNF, Placebo |
| NCT02660580 MSB11022 in Moderate to Severe Chronic Plaque Psoriasis | Psoriasis, Plaque Type Psoriasis | P3 | Completed | 443 | RCT, Double-blind | MSB11022, Humira® |
| NCT00094770 An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (0431-024) | Diabetes Mellitus, Type 2 | P3 | Completed | 1,172 | RCT, Double-blind | sitagliptin (MK0431), Comparator: glipizide |
| NCT04767373 Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) | Respiratory Syncytial Virus Infection | P2P3 | Completed | 3,632 | RCT, Double-blind | Clesrovimab, Placebo |
| NCT00617123 Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) | Atherosclerosis, Ischemia | P3 | Completed | 258 | RCT, Double-blind | Vorapaxar 2.5 mg, Placebo |
| NCT00131391 A Study of MK0364 in Obese Patients (0364-014) | Obesity | P3 | Terminated | 2,400 | RCT, Double-blind | Comparator: taranabant, Comparator: placebo |
| NCT02282020 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments | Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity | P3 | Completed | 266 | RCT, Open-label | OLAPARIB, Single agent chemotherapy |
| NCT05191797 Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer | Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma | P1P2 | Terminated | 3 | Open-label | Bomedemstat, Atezolizumab |
| NCT01058642 Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia | Postherpetic Neuralgia | P2 | Terminated | 41 | RCT, Double-blind | ADL5747, Placebo, Pregabalin |
| NCT01727336 Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | P2 | Terminated | 160 | RCT, Double-blind | Dalantercept and axitinib, Placebo and axitinib |
| NCT00652782 Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients | Congestive Heart Failure, Renal Impairment | P2 | Completed | 160 | RCT, Double-blind | rolofyline, Comparator Placebo (unspecified) |
| NCT01458392 Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck | P2 | Completed | 46 | Open-label | Dalantercept |
| NCT00097422 OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD) | Diarrhea | P2 | Completed | — | RCT, Open-label | OPT-80 |
| NCT00358930 A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | Head and Neck Neoplasms, Carcinoma, Squamous Cell | P2 | Completed | 60 | Open-label | ARQ 501 |
| NCT04254978 Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003) | Essential Thrombocythemia | P2 | Completed | 73 | Open-label | Bomedemstat |
| NCT01258569 Entereg Laparoscopic Colon Resection Study | Laparoscopic Colonic Resection | P2 | Completed | 135 | RCT, Double-blind | Entereg, Entereg, placebo |
| NCT03496207 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | P2 | Completed | 106 | RCT, Double-blind | Placebo, Sotatercept |
| NCT00428844 Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci | Osteomyelitis | P2 | Completed | 75 | RCT, Open-label | daptomycin, daptomycin, vancomycin, teicoplanin, nafcillin, oxacillin, flucloxacillin |
| NCT02733432 RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections | Candidiasis, Vulvovaginal, Mycoses | P2 | Completed | 126 | RCT, Open-label | CD101 Vaginal Gel (3%), CD101 External gel (1%), CD101 Vaginal Ointment (6%), CD101 External ointment (1%), Fluconazole |
| NCT04091360 A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease | COPD | P2 | Completed | 40 | RCT, Double-blind | Part A: RPL554, Placebos, Part B: RPL554 |
| NCT02476890 Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014) | Refractory Chronic Cough | P2 | Completed | 36 | RCT, Double-blind | Gefapixant 100 mg, Placebo |
| NCT02842827 A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) | Acute Myeloid Leukemia, Myelodysplastic Syndrome | P1P2 | Completed | 45 | Open-label | bomedemstat, tretinoin |
| NCT00622063 An Extension Study for Patients Previously Treated With ARQ 501 | Cancer | P1P2 | Completed | 1 | Open-label | ARQ 501 |
| NCT01749540 Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002) | B-Thalassemia | P2 | Completed | 64 | Open-label | luspatercept |
| NCT06854952 A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity | Overweight or Obesity | P2 | Completed | 167 | RCT, Double-blind | TERN-601 |
| NCT03136185 Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002) | Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF) | P1P2 | Completed | 90 | Open-label | Bomedemstat |
| NCT02927080 Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) | Facioscapulohumeral Muscular Dystrophy | P2 | Terminated | 95 | RCT, Double-blind | ACE-083, ACE-083 or placebo |
| NCT00331045 Clinical Evaluation Of Alvimopan (SB767905) On Constipation And Related Symptoms Associated With Opioid | Cancer, Constipation | P2 | Terminated | 21 | RCT, Double-blind | alvimopan, Placebo, Alvimopan 0.5 mg/day, Alvimopan 1 mg/day |
| NCT05558696 A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) | Polycythemia Vera | P2 | Completed | 20 | Open-label | Bomedemstat |
| NCT02397460 Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) | Refractory Chronic Cough | P2 | Completed | 50 | RCT, Double-blind | Gefapixant, Placebo |
| NCT00816023 A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume | Bloodloss, Surgical Procedures, Operative | P2 | Completed | 276 | RCT, Double-blind | ecallantide, placebo |
| NCT00310518 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma | Cancer | P2 | Completed | 30 | Open-label | ARQ 501 |
| NCT00448864 Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement | Blood Loss, Surgical | P2 | Terminated | 75 | RCT, Double-blind | Ecallantide, Placebo |
| NCT01275755 Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain | Constipation | P2 | Completed | 81 | RCT, Double-blind | Placebo, ADL5945 0.25 mg |
| NCT04945460 A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) | Hypertension, Pulmonary | P2 | Completed | 165 | RCT, Double-blind | Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg |
| NCT00695903 Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia | Endocarditis, Bacterial, Infective Endocarditis | P2 | Terminated | 38 | RCT, Double-blind | daptomycin, vancomycin |
| NCT02663622 Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002) | Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation | P2 | Completed | 44 | RCT, Double-blind | Efprezimod alfa, Methotrexate, Tacrolimus, Placebo |
| NCT02349425 A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010) | Refractory Chronic Cough | P2 | Completed | 59 | RCT, Double-blind | Gefapixant, Placebo (for gefapixant) |
| NCT01569438 The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) | Bladder Pain Syndrome | P2 | Terminated | 107 | RCT, Double-blind | Gefapixant, Placebo |
| NCT03443414 Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients | COPD | P2 | Completed | 405 | RCT, Double-blind | RPL554 suspension, Placebo |
| NCT02609984 Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | Sarcoma, Myxoid/Round Cell Liposarcoma | P2 | Terminated | 89 | RCT, Open-label | CMB305, atezolizumab |
| NCT02612610 A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012) | Refractory Chronic Cough | P2 | Completed | 253 | RCT, Double-blind | Gefapixant, Placebo (for gefapixant) |
| NCT02542254 The Effects of RPL554 on Top of Standard COPD Reliever Medications | Chronic Obstructive Pulmonary Disease | P2 | Completed | 36 | RCT, Double-blind | Salbutamol, Ipratropium, RPL554, Salbutamol matched placebo, Ipratropium matched placebo, RPL554 matched placebo |
| NCT05415722 DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis | P2 | Completed | 162 | RCT, Double-blind | TERN-501, TERN-101 |
| NCT02502097 A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | Idiopathic Pulmonary Fibrosis, Cough | P2 | Completed | 51 | RCT, Double-blind | Gefapixant |
| NCT04552704 CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | Advanced Malignant Solid Neoplasm | P1P2 | Terminated | 3 | RCT, Double-blind | CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration |
| NCT00507247 Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus | Staphylococcus Aureus | P2 | Completed | 11 | Open-label | Daptomycin |
| NCT03342404 A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia | Thalassemia | P2 | Completed | 145 | RCT, Double-blind | Luspatercept |
| NCT01993329 A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Participants With Asthma (MK-7264-009) | Asthma | P2 | Completed | 20 | RCT, Double-blind | Gefapixant 50 mg, Gefapixant 300 mg, Placebo to mimic 50 mg tablets, Placebo to mimic 300 mg tablets |
| NCT05013905 A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006) | Crohn Disease | P2 | Completed | 55 | RCT, Open-label | Tulisokibart |
| NCT02501473 Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142) | Follicular Low Grade Non-Hodgkin's Lymphoma | P1P2 | Terminated | 52 | RCT, Open-label | G100, Pembrolizumab, Rituximab |
| NCT03108066 MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | VHL Gene Mutation, VHL | P2 | Completed | 4 | Open-label | MK-3795 |
| NCT02268409 Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004) | β-Thalassemia | P2 | Completed | 51 | Open-label | luspatercept |
| NCT01178411 An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols | Advanced Solid Tumors | P1P2 | Completed | 60 | Open-label | Tivantinib, Anti-Cancer Combination Therapy |
| NCT00993863 Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction | Acute Pain | P2 | Completed | 201 | RCT, Double-blind | Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg |
| NCT00761215 Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections | Skin Diseases, Infectious, Skin Diseases, Bacterial | P2 | Completed | 192 | RCT, Double-blind | TR-701 200 mg, TR-701 300 mg, TR-701 400 mg |
| NCT03738150 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | P2 | Completed | 21 | Open-label | Sotatercept |
| NCT00467272 Catheter Related - Gram Positive Bloodstream Infections | Bloodstream Infection | P2 | Completed | 30 | Open-label | Daptomycin |
| NCT00228592 HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection | Hepatitis B, Liver Transplantation | P2 | Terminated | — | RCT, Open-label | HepeX-B, Hepatitis B Immune Globulin (HBIg) |
| NCT03577028 Study of HPN424 in Patients With Advanced Prostate Cancer | Advanced Prostate Cancer | P1P2 | Terminated | 104 | Open-label | HPN424 Fixed IV 1.3 to 150 ng/kg, HPN424 Prime Step IV 36 ng/kg Target, HPN424 1 Prime Step IV 225-300 ng/kg Target, HPN424 2 Prime Step IV 300 ng/kg Target, HPN424 2 Prime Step IV 450 ng/kg Target, HPN424 Fixed SC |
| NCT07132983 A Phase II Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Single Inhaled Doses of Ensifentrine-glycopyrrolate Fixed Dose Combination, Ensifentrine, and Glycopyrrolate in Subjects With Chronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease | P2 | Completed | 33 | RCT, Double-blind | Ensifentrine 3 mg, Glycopyrrolate 42.5 mcg, Ensifentrine 1.5 mg, Ensifentrine 3 mg (marketed formulation) |
| NCT03216499 HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma | Recurrent Glioblastoma | P2 | Completed | 24 | Open-label | HIF-2alpha Inhibitor PT2385 |
| NCT02477709 A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | P2 | Completed | 6 | Open-label | Gefapixant |
| NCT01070290 A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen | Gastric Cancer | P2 | Withdrawn | — | RCT, Open-label | ARQ 197, Oxaliplatin, capecitabine or irinotecan |
| NCT01554579 A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee | Osteoarthritis of the Knee | P2 | Completed | 171 | RCT, Double-blind | Gefapixant, Sugar Pill |
| NCT02303782 A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT) | Acute Myeloid Leukemia | P1P2 | Withdrawn | — | RCT, Open-label | OTX015, Vidaza (azacitidine) |
| NCT03673670 Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD | COPD | P2 | Completed | 79 | RCT, Double-blind | RPL554 Suspension, Placebo, Tiotropium/olodaterol (Respimat) |
| NCT02612623 An 8-Week Refractory Chronic Cough Study (MK-7264-021) | Refractory Chronic Cough | P2 | Completed | 24 | RCT, Double-blind | Gefapixant, Placebo (for gefapixant) |
| NCT03094832 Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002) | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | P1P2 | Terminated | 50 | Open-label | Miransertib |
| NCT00426933 Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections | Soft Tissue Infections | P2 | Completed | 100 | RCT, Open-label | Daptomycin, Vancomycin |
| NCT00159614 Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment | Heart Failure, Congestive, Renal Insufficiency | P2 | Completed | 30 | RCT, Double-blind | KW-3902IV |
| NCT01749514 Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001) | Anemia | P2 | Completed | 116 | Open-label | Luspatercept |
| NCT01752920 Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations | Solid Tumor | P1P2 | Completed | 119 | Open-label | Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D) |
| NCT00159627 Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF). | Heart Failure, Congestive | P2 | Completed | 52 | RCT, Double-blind | KW-3902IV |
| NCT02406781 Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial | Sarcoma | P2 | Completed | 129 | Open-label | Combination of MK3475 with Metronomic CP, Combination of MK3475 with Metronomic CP and G100 |
| NCT02919995 A Study of RPL554 in Patients With Cystic Fibrosis | Cystic Fibrosis | P2 | Completed | 10 | RCT, Double-blind | RPL554, Placebo |
| NCT00557609 Phase 2 Study in Patients With MiT Tumors | Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS) | P2 | Completed | 47 | Open-label | ARQ 197 |
| NCT06609460 Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications | Influenza | P2 | Completed | 5,071 | RCT, Double-blind | — |
| NCT05569538 Bomedemstat (IMG-7289) Plus Ruxolitinib for Myelofibrosis | Myelofibrosis | P2 | Unknown | 40 | Open-label | Bomedemstat |
| NCT00101998 Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication | Constipation, Bowel Dysfunction | P2 | Completed | 233 | RCT, Double-blind | alvimopan, placebo |
| NCT07016412 Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212) | Chronic Obstructive Pulmonary Disease | P2 | Completed | 497 | RCT, Double-blind | Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo |
| NCT06545500 A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD | Chronic Obstructive Pulmonary Disease | P2 | Completed | 46 | RCT, Double-blind | Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo |
| NCT04527471 Pilot Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19 | Coronavirus Infection, Covid-19 | P2 | Completed | 45 | RCT, Double-blind | Ensifentrine Dose 1, Placebo pMDI |
| NCT01147640 Safety and Efficacy Study to Compare IV CXA 101/Tazobactam and Metronidazole With Meropenem in Complicated Intraabdominal Infections | Complicated Intra-abdominal Infection | P2 | Completed | 122 | RCT, Double-blind | CXA-101/ tazobactam and metronidazole, meropenem plus saline placebo |
| NCT05523089 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults | Influenza | P2 | Completed | 59 | RCT, Double-blind | Saline placebo |
| NCT00888940 Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery | Bloodloss, Surgical Procedures, Operative | P2 | Completed | 243 | RCT, Double-blind | Ecallantide, Cyklokapron(R) |
| NCT02427165 Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients | Asthma | P2 | Completed | 29 | RCT, Double-blind | RPL554, Salbutamol, Placebo |
| NCT01146574 A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis. | Anemia | P2 | Completed | 50 | RCT, Single-blind | Sotatercept, Placebo |
| NCT00135577 Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects | Cancer, Bowel Dysfunction | P2 | Completed | 67 | Double-blind | alvimopan, placebo |
| NCT01395758 Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | P2 | Completed | 96 | RCT, Open-label | ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine |
| NCT03124459 Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease | Charcot-Marie-Tooth Disease | P2 | Terminated | 63 | RCT, Double-blind | ACE-083, Placebo |
| NCT01591863 Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) | Clostridium Difficile-associated Diarrhea | P2 | Completed | 38 | Open-label | fidaxomicin |
| NCT00603265 Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy | Peripheral Neuropathy, Neuropathic Pain | P2 | Completed | 226 | RCT, Double-blind | ADL5859, Duloxetine, Placebo |
| NCT03028142 The Effects of RPL554 in Addition to Tiotropium in COPD Patients | Chronic Obstructive Pulmonary Disease Moderate | P2 | Completed | 30 | RCT, Double-blind | 1.5 mg RPL554 plus tiotropium, 6 mg RPL554 plus tiotropium, Placebo plus tiotropium |
| NCT00558207 A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Pancreatic Neoplasms | P2 | Completed | 43 | RCT, Open-label | ARQ 197, gemcitabine |
| NCT00988741 Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy | Unresectable Hepatocellular Carcinoma | P2 | Completed | 107 | RCT, Double-blind | ARQ 197, Placebo |
| NCT01519778 A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study | Major Cutaneous Abscess, Cellulitis | P2 | Completed | 200 | Open-label | TR701 FA |
| NCT01432730 A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006) | Chronic Cough | P2 | Completed | 24 | RCT, Double-blind | Gefapixant, Placebo |
| NCT04996797 A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005) | Ulcerative Colitis | P2 | Completed | 178 | RCT, Double-blind | Tulisokibart |
| NCT03943290 Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) | Facioscapulohumeral Muscular Dystrophy, Charcot-Marie-Tooth Disease | P2 | Terminated | 62 | RCT, Open-label | ACE-083 |
| NCT04060407 CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) | Metastatic Melanoma | P1P2 | Withdrawn | — | Open-label | CD24Fc, Ipilimumab, Nivolumab |
| NCT04504916 A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer | P2 | Terminated | 102 | Open-label | Zilovertamab vedotin |
| NCT01085591 Study of CB-183,315 in Participants With Clostridium Difficile Infection | Clostridium Difficile Infection, Diarrhea | P2 | Completed | 210 | RCT, Double-blind | CB-183,315, Placebo, Vancomycin |
| NCT01099761 Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P2 | Terminated | 24 | RCT, Double-blind | ACE-031 0.5 mg/kg q4wk, ACE-031 1.0 mg/kg q2wk |
| NCT04328077 LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH) | NASH - Nonalcoholic Steatohepatitis | P2 | Completed | 101 | RCT, Double-blind | TERN-101 |
| NCT00921024 Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections | Complicated Urinary Tract Infection | P2 | Completed | 129 | RCT, Double-blind | CXA-101, Ceftazidime |
| NCT03960541 Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003) | HIV Infections, Dyslipidemias | P2 | Terminated | 8 | RCT, Double-blind | Efprezimod alfa (human CD24 extracellular domain and human IgG1 Fc fusion protein), Saline Solution |
| NCT01239758 Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | P2 | Terminated | 11 | Open-label | ACE-031 (Extension of cohort 1 from core study, A031-03), ACE-031 (Extension of cohort 2 from core study, A031-03), ACE-031 (Extension of cohort 3 from core study, A031-03) |
| NCT04027439 Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler | Pulmonary Disease, Chronic Obstructive | P2 | Completed | 37 | RCT, Double-blind | Part A: RPL554, Part B: RPL554, Placebos |
| NCT00979953 Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee | Osteoarthritis of the Knee | P2 | Completed | 408 | RCT, Double-blind | ADL5859, ADL5747, Oxycodone CR, Placebo |
| NCT02268383 Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003) | Myelodysplastic Syndromes | P2 | Completed | 75 | Open-label | Luspatercept |
| NCT05223920 An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | Thrombocythemia, Essential, Primary Myelofibrosis | P2 | Completed | 81 | Open-label | Bomedemstat |
| NCT00102700 ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer | Pancreatic Cancer, Adenocarcinoma | P2 | Completed | 66 | Open-label | ARQ 501 in combination with gemcitabine |
| NCT02734862 CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension | Candidemia, Mycoses | P2 | Completed | 207 | RCT, Double-blind | CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo |
| NCT01207427 Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain | Opioid Induced Constipation | P2 | Completed | 131 | RCT, Double-blind | Placebo, ADL5945 0.1 mg, ADL5945 0.25 mg |
| NCT02024087 Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | Advanced Adult Hepatocellular Carcinoma | P1P2 | Completed | 21 | Open-label | Dalantercept plus sorafenib |
| NCT00777309 A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer | P2 | Completed | 167 | RCT, Double-blind | ARQ 197, Erlotinib, Placebo |
| NCT02296476 A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002) | Glioblastoma Multiforme | P2 | Terminated | 12 | Open-label | Birabresib |
| NCT03937479 Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | COPD | P2 | Completed | 416 | RCT, Double-blind | Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium, Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium |
| NCT00626275 Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis | Rheumatoid Arthritis | P2 | Completed | 46 | RCT, Double-blind | ADL5859, Naproxen, Placebo, ADL5859, Placebo |
| NCT00732810 SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) | Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | P2 | Completed | 97 | RCT, Open-label | SCH 727965, Capecitabine, Erlotinib |
| NCT01564459 Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) | Diabetic Neuropathy, Painful | P2 | Completed | 170 | RCT, Double-blind | MK-6096, Placebo |
| NCT01527383 A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009) | Herpes Zoster | P2 | Completed | 354 | RCT, Double-blind | V212, Placebo |
| NCT05258279 Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | Non-squamous Non-small-cell Lung Cancer, EGFR Activating Mutation | P2 | Completed | 30 | Open-label | Pembrolizumab, Lenvatinib, Carboplatin, Pemetrexed |
| NCT03887442 Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy | Head and Neck Cancer | P2 | Terminated | 17 | RCT, Open-label | Paclitaxel, Cetuximab + Paclitaxel |
| NCT03012620 Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types | Sarcoma, Ovarian Neoplasm | P2 | Completed | 334 | Open-label | Pembrolizumab |
| NCT04209686 Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma | Advanced Gastric Adenocarcinoma | P2 | Completed | 19 | Open-label | Paclitaxel, Olaparib, Pembrolizumab |
| NCT00787527 SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | Lymphoma | P1P2 | Completed | 14 | Open-label | Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone |
| NCT07876128 A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) | Advanced Solid Tumors, Malignant Neoplasm | P1P2 | Not Yet Recruiting | 300 | RCT, Open-label | MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist, Corticosteroid, Steroid mouthwash (dexamethasone or equivalent) |
| NCT03547583 Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF | Chronic Heart Failure With Preserved Ejection Fraction | P2 | Completed | 789 | RCT, Double-blind | Vericiguat (BAY1021189) 2.5 mg, 5 mg or 10 mg IR tablets, Placebo |
| NCT01735422 A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women | Infertility | P2 | Completed | 67 | RCT, Open-label | r-hFSH, r-hLH, u-hCG |
| NCT03139851 Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide | Metastatic Breast Cancer | P2 | Completed | 36 | Open-label | Cyclophosphamide 50mg, Pembrolizumab 100 MG in 4 ML Injection |
| NCT03407170 Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | Advanced Melanoma | P2 | Terminated | 1 | Open-label | pembrolizumab |
| NCT00260039 Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001) | HPV, Cervical Cancer | P2 | Completed | 680 | RCT, Double-blind | Comparator: Gardasil, Comparator: octavalent HPV Vaccine - dose formulation 1, Comparator: octavalent HPV Vaccine - dose formulation 2, Comparator: octavalent HPV Vaccine - dose formulation 3 |
| NCT00638963 Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) | Breast Neoplasm, Brain Neoplasm | P2 | Terminated | 6 | RCT, Open-label | temozolomide |
| NCT01717287 A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248) | HIV Infection | P2 | Completed | 32 | Open-label | Raltegravir Film-coated Tablet, Raltegravir Chewable Tablet, Other Anti-Retroviral Therapy |
| NCT00103714 Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease | Cystic Fibrosis | P2 | Completed | 72 | RCT, Double-blind | denufosol tetrasodium (INS37217) |
| NCT01523639 A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis | Colorectal Cancer, Steatohepatitis | P2 | Terminated | 8 | RCT, Double-blind | Metformin/Placebo |
| NCT03631407 Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | Colorectal Neoplasms | P2 | Completed | 41 | RCT, Open-label | Vicriviroc, Pembrolizumab |
| NCT01432574 Study of Gardasil in Mid-Adult Males (MAM) | Human Papillomavirus | P2 | Completed | 150 | Open-label | Gardasil |
| NCT05061420 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204) | Squamous Cell Carcinoma of Head and Neck | P2 | Terminated | 59 | Open-label | Pembrolizumab, SAR444245 (Thor-707), Cetuximab |
| NCT02964559 Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma | P2 | Completed | 11 | Open-label | Pembrolizumab |
| NCT03278405 Avelumab in G3 NEC | Neuroendocrine Carcinoma | P1P2 | Completed | 10 | Open-label | Avelumab |
| NCT03693170 Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer | BRAF V600E-mutant Metastatic Colorectal Cancer | P2 | Completed | 95 | Open-label | encorafenib, Binimetinib, Cetuximab |
| NCT05255666 Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM) | Triple Negative Breast Cancer, Brain Metastases | P2 | Withdrawn | — | Open-label | Pembrolizumab, Liposomal Irinotecan |
| NCT05617313 Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer, Metastatic NSCLC | P2 | Terminated | 21 | Open-label | Pembrolizumab, GT103 |
| NCT01096667 Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042) | Diabetes Mellitus, Type 2, Hypertension | P2 | Completed | 194 | RCT, Double-blind | Placebo to Ertuglilflozin 1 or 5 mg, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, HCTZ 12.5mg, Placebo to HCTZ, Placebo to ertuglilflozin 25 mg |
| NCT02987972 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008) | Pneumococcal Infections | P2 | Completed | 1,051 | RCT, Double-blind | V114 Lot 1, V114 Lot 2, Prevnar 13™ |
| NCT00127192 A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044) | Type 2 Diabetes Mellitus | P2 | Completed | 363 | RCT, Double-blind | sitagliptin phosphate, Comparator: placebo (unspecified) |
| NCT00243230 Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) | HIV Infections | P2 | Completed | 116 | RCT, Double-blind | Vicriviroc 30 mg, Vicriviroc 20 mg, Placebo, Placebo, Background ART Regimen |
| NCT02097108 Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir | HIV Infections | P2 | Completed | 11 | Open-label | Raltegravir |
| NCT02335424 Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052) | Urothelial Cancer | P2 | Completed | 374 | Open-label | pembrolizumab |
| NCT02178722 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer | P1P2 | Completed | 444 | Open-label | MK-3475, INCB024360 |
| NCT03245151 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors | Recurrent and Refractory Solid Tumors | P1P2 | Completed | 64 | Open-label | Lenvatinib, Everolimus |
| NCT03322566 A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06) | Lung Cancer | P2 | Completed | 233 | RCT, Double-blind | Pembrolizumab, Epacadostat, Platinum-based chemotherapy, Placebo |
| NCT03812796 Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) | Cancer, GI Cancer | P2 | Unknown | 75 | Open-label | Domatinostat, Avelumab |
| NCT00894569 Paclitaxel/Carboplatin With or Without Cetuximab in CUP | Neoplasms, Unknown Primary, Carcinoma | P2 | Unknown | 150 | RCT, Open-label | paclitaxel/carboplatin, cetuximab |
| NCT00831545 Study to Evaluate the Efficacy and Safety of Temozolomide in Subjects With Brain Metastases of Either Malignant Melanoma, Breast, or Non-small Cell Lung Cancer (P02064) | Metastases of Central Nervous System, Melanoma | P2 | Completed | 162 | Open-label | Temozolomide |
| NCT03477175 Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials | Solid Tumors | P2 | Completed | 40 | Open-label | E7080, Comparator Drug, Comparator Drug: Sorafenib |
| NCT00968617 A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002) | Anemia, Chronic Kidney Disease | P2 | Terminated | 7 | RCT, Open-label | MK2578, MK2578, MK2578, Comparator: darbepoetin alfa |
| NCT00475735 A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) | Attention-Deficit/Hyperactivity Disorder (ADHD) | P2 | Completed | 72 | RCT, Double-blind | MK0249, Concerta (methylphenidate), Placebo |
| NCT00551018 Efficacy and Safety of VICRIVIROC in HIV-Infected Treatment-Naïve Subjects (Study P04875) | HIV Infections | P2 | Completed | 218 | RCT, Open-label | Vicriviroc, emtricitabine and tenofovir disoproxil fumarate |
| NCT02688608 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer | Anaplastic Thyroid Cancer | P2 | Completed | 6 | Open-label | Pembrolizumab |
| NCT03506997 Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer | Castration-resistant Prostate Cancer | P2 | Unknown | 100 | Open-label | Pembrolizumab |
| NCT01165320 A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074) | Candidiasis, Esophageal, Candidiasis, Invasive | P2 | Completed | 20 | Open-label | Caspofungin |
| NCT00362024 MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED) | Alzheimer's Disease | P2 | Terminated | 24 | RCT, Double-blind | MK0952, Comparator: Placebo |
| NCT01758588 Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis | Myelofibrosis | P2 | Terminated | 8 | RCT, Open-label | Peginterferon alfa-2a |
| NCT00988728 Efficacy & Safety of SCH 900435 in Schizophrenia (Study P06079)(WITHDRAWN) | Schizophrenia | P2 | Withdrawn | — | RCT, Double-blind | SCH 900435 (Org 25935), Placebo, Olanzapine |
| NCT01720875 Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) | Multiple Myeloma | P2 | Completed | 16 | Open-label | Vorinostat Velcade Dexamethasone |
| NCT01059825 Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016) | Diabetes Mellitus, Type 2 | P2 | Completed | 375 | RCT, Double-blind | Placebo to Ertugliflozin, Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg, Sitagliptin 100 mg, Placebo to Sitagliptin, Metformin |
| NCT00424424 A Study to Evaluate the Efficacy of MK0719 in the Prevention of Postoperative Dental Pain (0719-002) | Pain, Postoperative | P2 | Terminated | 81 | RCT, Double-blind | MK0719 |
| NCT00439517 Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. | Previously Untreated Metastatic Colorectal Cancer | P2 | Completed | 302 | RCT, Open-label | UFOX + Cetuximab, FOLFOX4 + Cetuximab |
| NCT05156268 A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma | Endometrial Carcinosarcoma | P2 | Completed | 26 | Open-label | Pembrolizumab, Olaparib |
| NCT02549209 Pembro/Carbo/Taxol in Endometrial Cancer | Endometrial Cancer, Endometrial Adenocarcinoma | P2 | Completed | 46 | Open-label | Pembrolizumab, Paclitaxel, Carboplatin |
| NCT01513551 The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002) | Pneumococcal Infections | P2 | Completed | 692 | RCT, Double-blind | Pneumococcal Conjugate Vaccine (V114), PNEUMOVAX® 23, PREVNAR 13® |
| NCT02573181 Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007) | Pneumococcal Infections | P2 | Completed | 253 | RCT, Double-blind | V114, Prevnar 13™ |
| NCT03217136 MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035) | Complicated Intra-Abdominal Infection | P2 | Completed | 94 | RCT, Double-blind | Ceftolozane/Tazobactam, Metronidazole, Meropenem, Placebo for Metronidazole |
| NCT01066871 Sprifermin (AS902330) in Cartilage Injury Repair (CIR) | Isolated Cartilage Injury of the Knee | P2 | Terminated | 74 | RCT, Double-blind | Sprifermin (AS902330) 10 mcg, Sprifermin (AS902330) 30 mcg, Sprifermin (AS902330) 100 mcg |
| NCT00504530 r-hLIF for Improving Embryo Implantation in IVF | Infertility Implantation Failure | P1P2 | Completed | 50 | RCT, Double-blind | Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF) |
| NCT03160079 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts | B-Cell Acute Lymphoblastic Leukemia, Adult | P1P2 | Completed | 16 | Open-label | blinatumomab, pembrolizumab |
| NCT03664024 Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) | Non-Small Cell Lung Cancer | P2 | Completed | 118 | Open-label | Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin |
| NCT02212379 Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL | HIV-1 Infection | P2 | Completed | 170 | Open-label | raltegravir and etravirine |
| NCT04914897 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) | Pleural Mesothelioma, Non-small Cell Lung Cancer | P2 | Terminated | 106 | Open-label | THOR-707, Pembrolizumab |
| NCT02705820 Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy | Metastatic Non Small Cell Lung Cancer | P2 | Completed | 48 | Open-label | Pembrolizumab |
| NCT01492582 Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors | Cancer Survivor, Prevention of Human Papillomavirus Infection | P2 | Completed | 1,499 | Open-label | quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) |
| NCT04807816 Targeting ATR in Soft-tissue Sarcomas | Leiomyosarcoma, Adult | P2 | Completed | 58 | RCT, Open-label | Association of berzosertib with gemcitabine, Gemcitabine |
| NCT00551187 A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED) | Cervical Cancer, Vulvar Cancer | P2 | Completed | 620 | RCT, Double-blind | V504, Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine, Comparator: Placebo (unspecified) |
| NCT00553514 AS900672-Enriched in Ovulation Induction | Ovulation Induction | P2 | Terminated | 71 | RCT, Single-blind | AS900672-Enriched 10 microgram (mcg), AS900672-Enriched 20 mcg, AS900672-Enriched 30 mcg, AS900672-Enriched 40 mcg, Follitropin alfa 75 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG) |
| NCT00704184 Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) | Hepatitis C | P2 | Completed | 95 | RCT, Double-blind | Comparator: Vaniprevir, Comparator: Pegylated-Interferon (Peg-IFN), Comparator: Ribavirin, Comparator: placebo |
| NCT02490436 Novel Treatment Option for Neuropathic Pain | Neuralgia, Complex Regional Pain Syndromes | P2 | Completed | 15 | RCT, Double-blind | Cetuximab, Placebo |
| NCT00503971 Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. | Non-small Cell Lung Cancer | P1P2 | Terminated | 33 | Open-label | Vorinostat plus Erlotinib |
| NCT03818893 Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | Advanced Melanoma | P2 | Unknown | 46 | Open-label | Combination of GEN0101 and Pembrolizmub |
| NCT00330395 Open, Pharmacokinetic Study of Caspofungin in Neonates and Infants (0991-058) | Candidiasis | P2 | Completed | 16 | Open-label | caspofungin acetate |
| NCT00729222 Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503) | Heart Failure | P2 | Completed | 60 | RCT, Double-blind | Comparator: Placebo, rolofylline |
| NCT04158700 A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer | Advanced Cancer | P1P2 | Withdrawn | — | Open-label | LY3200882, Pembrolizumab |
| NCT00506987 Study of the Efficacy and Safety of SCH 486757 in Subjects With Chronic Cough (Study P04887) | Cough | P2 | Completed | 31 | RCT, Double-blind | SCH 486757, Placebo Dose 1 |
| NCT00282763 A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005) | Neuralgia, Postherpetic | P2 | Terminated | 12 | RCT, Double-blind | MK0686 |
| NCT00505752 Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART) | Infertility | P2 | Completed | 520 | RCT, Single-blind | AS900672-Enriched 50 microgram (mcg), AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Recombinant human chorionic gonadotropin (r-hCG) |
| NCT02039674 A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | Non-small Cell Lung Carcinoma | P1P2 | Completed | 267 | RCT, Open-label | Pembrolizumab, Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed, Ipilimumab, Erlotinib, Gefitinib |
| NCT00572910 A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) | Staphylococcus Aureus Infection | P2 | Completed | 206 | RCT, Double-blind | Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO), V710 Comparator: Placebo (PBO) |
| NCT00120835 Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C | Chronic Hepatitis C | P1P2 | Completed | — | RCT, Open-label | valopicitabine, pegylated interferon |
| NCT00539578 Treatment of Patients With Anxiety Disorder (0777-022) | Generalized Anxiety Disorder | P2 | Completed | 270 | RCT, Double-blind | MK0777, Comparator: placebo (unspecified) |
| NCT00880763 A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016) | Hepatitis C | P2 | Completed | 90 | RCT, Double-blind | Vaniprevir, Pegylated Interferon (peg-IFN), Ribavirin, Comparator: Placebo |
| NCT03242915 Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | Non-small Cell Lung Cancer | P2 | Completed | 33 | Open-label | Pembrolizumab, Carboplatin, Pemetrexed |
| NCT00600691 The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy | Hematuria, Hematospermia | P2 | Terminated | 29 | RCT, Double-blind | Finasteride |
| NCT01181622 A Safety and Tolerability Study of Denufosol in 2-4 Year Olds | Cystic Fibrosis | P2 | Completed | 25 | RCT, Double-blind | denufosol tetrasodium Inhalation Solution, 0.9% w/v sodium chloride solution |
| NCT01057511 Compare the Difference of P4 Concentration in Serum and Endometrium After Vaginal and IM P Administration | Postmenopausal Endometrium | P1P2 | Completed | 51 | RCT, Single-blind | Crinone 8%, Progesterone |
| NCT01094548 Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy | Multiple Myeloma | P2 | Completed | 34 | RCT, Open-label | Tecemotide (L-BLP25), Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide |
| NCT00325455 MK0859 Dose-Ranging Study (0859-003) | Hypercholesterolemia, Mixed Hyperlipemia | P2 | Terminated | 500 | RCT, Double-blind | MK0859 |
| NCT02348008 Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma: | Clear Cell Renal Carcinoma | P1P2 | Completed | 61 | Open-label | MK-3475, Bevacizumab, MK-3475, Bevacizumab |
| NCT02677155 Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma | Follicular Lymphoma | P2 | Completed | 10 | Open-label | Rituximab, Autologous dendritic cells, GM-CSF, Pembrolizumab |
| NCT02500121 Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer | Urothelial Carcinoma, Bladder Cancer | P2 | Completed | 108 | RCT, Double-blind | Pembrolizumab |
| NCT00533676 Endpoint Validation Study (0524A-015) | Flushing | P2 | Completed | 165 | RCT, Double-blind | MK0524A, /Duration of Treatment : 8 Weeks, Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks |
| NCT03322540 Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | Lung Cancer | P2 | Completed | 154 | RCT, Double-blind | Pembrolizumab, Epacadostat, Placebo |
| NCT00574587 Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | Breast Cancer | P1P2 | Completed | 55 | Open-label | Vorinostat, Paclitaxel, Trastuzumab, Doxorubicin, Cyclophosphamide |
| NCT04564547 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] | HIV-1 Infection | P2 | Completed | 161 | RCT, Double-blind | Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF |
| NCT04624243 Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008) | Schizophrenia | P2 | Completed | 499 | RCT, Double-blind | Elpipodect, Risperidone, Placebo to MK-8189, Placebo to risperidone |
| NCT00002225 A Study of Efavirenz in Combination With Stavudine and Didanosine | HIV Infections | P2 | Completed | 60 | — | Efavirenz, Stavudine, Didanosine |
| NCT06805864 Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma | Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | P2 | Not Yet Recruiting | 45 | Open-label | Pembrolizumab (KEYTRUDA®) |
| NCT00508664 Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) | Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma | P2 | Completed | 180 | RCT, Open-label | Cetuximab, Docetaxel, Cisplatin (TP), 5-Fluorouracil (TPF) (only until Feb 2009) |
| NCT00807443 Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1 | HIV-1, HIV Infections | P2 | Completed | 10 | Open-label | Raltegravir |
| NCT07716917 Genitourinary Tumors With Sacituzumab Tirumotecan | Papillary Renal Carcinoma, Variant Histology Urothelial Carcinoma | P2 | Not Yet Recruiting | 100 | Open-label | Sacituzumab Tirumotecan (SKB264) |
| NCT00725725 Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) | Panic Disorder | P2 | Terminated | 46 | RCT, Double-blind | Org 25935, Org 25935, Placebo |
| NCT00836927 Extension Trial of Deforolimus (Ridaforolimus, MK-8669) in Participants With Advanced Cancer (MK-8669-038) | Advanced Cancers | P2 | Terminated | 7 | Open-label | Ridaforolimus Tablet, Ridaforolimus Intravenous (IV) Infusion |
| NCT04224740 Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer | Penile Carcinoma | P2 | Completed | 37 | Open-label | Pembrolizumab, Standard of care therapy |
| NCT04489940 Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | P2 | Terminated | 11 | Open-label | Bintrafusp alfa |
| NCT02116660 Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) | HIV Infections | P2 | Terminated | 11 | RCT, Open-label | Raltegravir (MK-0518), Nevirapine, Lamivudine, Tenofovir, Emtricitabine, Lopinavir, Ritonavir, Atazanavir, Darunavir |
| NCT02982720 Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron | Advanced Cholangiocarcinoma | P2 | Terminated | 4 | Open-label | Pembrolizumab, Sylatron |
| NCT00971932 Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Squamous Cell Carcinoma of the Head and Neck | P2 | Completed | 33 | Open-label | Cetuximab, Cisplatin/Carboplatin, 5-Fluorouracil |
| NCT00642993 Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED) | Obesity, Overweight | P2 | Completed | 401 | RCT, Double-blind | SCH 497079, Placebo |
| NCT02054442 A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck | Squamous Cell Carcinoma of the Head and Neck | P1P2 | Unknown | 52 | RCT, Open-label | Cetuximab, Methotrexate |
| NCT04003103 Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016) | HIV-1 Infection | P2 | Completed | 242 | RCT, Double-blind | Islatravir, Placebo |
| NCT00798213 SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute | P2 | Terminated | 29 | RCT, Open-label | SCH 727965, Gemtuzumab ozogamicin |
| NCT03598608 Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | Hodgkin Disease, Lymphoma, Non-Hodgkin | P1P2 | Terminated | 137 | Open-label | pembrolizumab, Favezelimab |
| NCT02122861 Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 | Melanoma - Currently Enrolling, Non-small Cell Lung Cancer - Enrollment Completed | P1 | Completed | 47 | Open-label | ID-LV305 |
| NCT01442831 Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects | Healthy | P1 | Completed | 6 | Open-label | Human ADME |
| NCT00658554 Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers | Healthy | P1 | Completed | 24 | RCT, Open-label | ARQ 197 |
| NCT05285137 Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects | Healthy | P1 | Completed | 77 | RCT, Double-blind | Saline placebo |
| NCT00679835 PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections | Gram Positive Infection, Concurrent Antibiotic Treatment | P1 | Completed | 24 | Open-label | daptomycin |
| NCT01461460 A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects | Healthy Volunteer | P1 | Completed | 48 | RCT, Double-blind | TR-701 FA 1200 mg, Moxifloxacin 400 mg, TR-701 FA 200 mg plus Placebo, Placebo |
| NCT01225536 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations | Solid Tumor | P1 | Completed | 24 | Open-label | ARQ 736 |
| NCT00671359 Food Effects of Single Oral Dose of 600mg TR-701 | Healthy | P1 | Completed | 12 | RCT, Open-label | TR-701 600mg |
| NCT01577459 A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response | Healthy Subjects | P1 | Completed | 18 | RCT, Double-blind | TR-701 FA with PSE |
| NCT03478319 A Study of ACE-2494 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 48 | RCT, Double-blind | ACE-2494 or placebo |
| NCT02387125 Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | Sarcoma, Melanoma | P1 | Terminated | 79 | Open-label | CMB305, G100, Metronomic CPA |
| NCT01724320 A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors | Solid Tumors | P1 | Unknown | 20 | Open-label | OTX008 |
| NCT00524524 An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 9 | Open-label | ARQ 501 |
| NCT00651638 A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype | Healthy | P1 | Completed | 17 | Open-label | Treatment with ARQ 197 |
| NCT00612703 A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | Cancer | P1 | Completed | 32 | Open-label | ARQ 197 |
| NCT01019395 Pharmacokinetics (PK) and Safety Evaluation of Daptomycin in Children Ages 3-24 Months With Proven or Suspected Gram-positive Infections or Peri-Operative Subjects Receiving Prophylactic Antibiotics | Gram Positive Bacterial Infection | P1 | Completed | 23 | Open-label | Daptomycin |
| NCT01713582 A Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/ Birabresib (MK-8628) in Hematologic Malignancies (MK-8628-001) | Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma | P1 | Completed | 141 | Open-label | OTX015/Birabresib |
| NCT00075933 ARQ 501 in Subjects With Cancer | Cancer | P1 | Completed | 80 | Open-label | ARQ 501 |
| NCT05603182 A Study of PRA052 in Healthy Volunteers | Healthy | P1 | Completed | 96 | RCT, Double-blind | PRA052 |
| NCT02492776 A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations | Healthy | P1 | Completed | 14 | Open-label | Omeprazole, Gefapixant, Gefapixant |
| NCT00876655 Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate | Healthy | P1 | Completed | 12 | RCT, Open-label | TR-701 di-sodium phosphate salt, TR-701 free acid phosphate |
| NCT04222985 Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2 | Genital Herpes | P1 | Terminated | 24 | RCT, Double-blind | HSV 2 Formulation 1, HSV 2 Formulation 2, HSV 2 Formulation 3, HSV 2 Formulation 4, HSV 2 Formulation 5, HSV 2 Formulation 6, Sodium Chloride 0.9% |
| NCT00755638 A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1)in Healthy Postmenopausal Volunteers | Muscle Loss | P1 | Completed | 48 | RCT, Double-blind | ACE-031 |
| NCT03872206 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression | Advanced Cancers Associated With Mesothelin Expression | P1 | Completed | 95 | Open-label | HPN536 Fixed IV 6 to 560 ng/kg, HPN536 1 Prime Step IV 600-1200 ng/kg Target, 2 Prime Step IV 900-14000 ng/kg Target |
| NCT00490737 Safety Study to Evaluate Daptomycin in Non-infected Adults Who Are Either on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis (MK-3009-021) | End-Stage Renal Disease | P1 | Completed | 12 | Open-label | daptomycin |
| NCT02229877 A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264) | Healthy Volunteers | P1 | Completed | 18 | Single-blind | Omeprazole, Gefapixant, Gefapixant, Gefapixant |
| NCT01452828 A Pharmacokinetics and Safety Study in Subjects With Renal Impairment | Renal Impairment | P1 | Completed | 24 | Open-label | TR-701 FA single infusion, TR-701 FA, TR-701 FA |
| NCT00671814 Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults | Healthy Subjects | P1 | Completed | 80 | RCT, Double-blind | TR-701, linezolid, placebo |
| NCT07838987 A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014) | Healthy | P1 | Completed | 196 | RCT, Open-label | Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine |
| NCT00983255 Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA) | Bacterial Infections | P1 | Completed | 90 | RCT, Double-blind | TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets |
| NCT00874042 Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 74 | Open-label | Treatment with ARQ 197 in combination with gemcitabine |
| NCT02553356 PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers | Healthy | P1 | Completed | 16 | RCT, Open-label | PT2385 |
| NCT00882557 Study to Evaluate Daptomycin Given During Dialysis and After Dialysis | End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis | P1 | Completed | 16 | RCT, Open-label | daptomycin, daptomycin |
| NCT01502800 Clinical Trial of ARQ 761 in Advanced Solid Tumors | Solid Tumors | P1 | Completed | 91 | RCT, Open-label | ARQ 761, ARQ 761 Weekly Administration, Bi-Weekly Administration of ARQ 761, Two Consecutive Weeks Administration of ARQ 761 with one week of rest |
| NCT00136292 Study of Single Dose Daptomycin in Pediatric Patients With Gram-positive Infection for Which They Are Receiving Standard Antibiotics | Gram-positive Bacterial Infections | P1 | Completed | 33 | Open-label | daptomycin |
| NCT01397604 The Effects of GLA on Human Volunteers | Healthy Volunteers | P1 | Completed | 32 | RCT, Double-blind | GLA-AF, GLA-SE |
| NCT02259114 A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | NUT Midline Carcinoma, Triple Negative Breast Cancer | P1 | Completed | 47 | Open-label | Birabresib |
| NCT02551549 An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects | Healthy | P1 | Completed | 24 | RCT, Double-blind | CD101 IV, Placebo |
| NCT02015416 A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer | Melanoma, Ovarian Cancer | P1 | Completed | 13 | Open-label | IDC-G305 |
| NCT00302172 ARQ 197 in Subjects With Metastatic Solid Tumors | Cancer, Tumor | P1 | Completed | 78 | Open-label | ARQ 197 |
| NCT01623401 A Phase 1, Open-Label, 10 Day Safety Study | Healthy Subjects | P1 | Completed | 72 | Open-label | TR-701 FA |
| NCT01539473 A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge | Healthy Volunteers | P1 | Completed | 30 | RCT, Double-blind | TR-701 FA with Tyramine, Placebo-controlled withTyramine |
| NCT00825487 Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies | Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies | P1 | Completed | 50 | Open-label | ARQ 621 |
| NCT00612209 A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors | Cancer, Advanced Solid Tumors | P1 | Completed | 51 | Open-label | ARQ 197 |
| NCT04948554 A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002) | Systemic Sclerosis With and Without Interstitial Lung Disease | P1 | Terminated | 5 | RCT, Double-blind | MK-2225, Placebo |
| NCT00666601 Microdialysis and Pharmacokinetic Study of TR-701 | Healthy | P1 | Completed | 15 | Open-label | TR-700 (active moiety), TR-701 (pro-drug) |
| NCT02083627 A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects | Drug-Drug Interaction (DDI), Intestinal Absorption | P1 | Completed | 25 | RCT, Open-label | rosuvastatin, fidaxomicin |
| NCT00709540 A Safety, Tolerability and Pharmacodynamics Study of ACE-011 (ActRIIA-IgG1) in Healthy Postmenopausal Women | Osteoporosis | P1 | Completed | 40 | RCT, Double-blind | ACE-011 or placebo |
| NCT03445169 A Food Effect Study in Healthy Volunteers With Belzutifan (PT2977, MK-6482) Tablets | Healthy | P1 | Completed | 16 | RCT, Open-label | Belzutifan |
| NCT02035657 A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | Merkel Cell Carcinoma | P1 | Completed | 10 | Open-label | GLA-SE |
| NCT00099190 ARQ 501 in Combination With Docetaxel in Patients With Cancer | Carcinoma | P1 | Completed | 50 | Open-label | ARQ 501 |
| NCT03833180 A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | P1 | Completed | 91 | Open-label | Zilovertamab vedotin |
| NCT02790840 A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations | Healthy | P1 | Completed | 32 | Open-label | Omeprazole, Omeprazole, Gefapixant, Gefapixant |
| NCT04897594 AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis | NASH - Nonalcoholic Steatohepatitis | P1 | Completed | 52 | RCT, Double-blind | TERN-201 |
| NCT02508740 Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment | Renal Impairment | P1 | Terminated | 31 | RCT, Open-label | bevenopran |
| NCT02508753 Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects | Healthy | P1 | Completed | 52 | RCT, Double-blind | CXA-101/tazobactam, CXA-101/tazobactam, Moxifloxacin, placebo |
| NCT01473095 Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | Solid Tumor, Malignant Lymphoma | P1 | Completed | 120 | Open-label | ARQ 092 |
| NCT02761694 Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001) | Cancer, Solid Tumors | P1 | Terminated | 78 | Open-label | Vevorisertib, Fulvestrant, Paclitaxel |
| NCT01271998 Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg | Bacterial Infection | P1 | Completed | 20 | Open-label | TR-701 FA |
| NCT02652936 A Pharmacokinetics Study of AF-130 in Healthy Subjects | Healthy Volunteers | P1 | Completed | 80 | RCT, Double-blind | AF-130, Placebo comparator |
| NCT05619536 Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects | Healthy | P1 | Completed | 28 | RCT, Double-blind | Saline placebo |
| NCT00802555 Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) | Cirrhosis, Hepatocellular Carcinoma | P1 | Completed | 21 | Open-label | ARQ 197 |
| NCT02387372 Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007) | Critically Ill, Pneumonia | P1 | Completed | 37 | Open-label | Ceftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose |
| NCT04676178 A Study of PRA023 in Healthy Volunteers | Healthy | P1 | Completed | 69 | RCT, Double-blind | PRA023 |
| NCT01431833 A PK and Safety Study in Subjects With Hepatic Impairment | Hepatic Impairment | P1 | Completed | 32 | Open-label | TR-701 FA |
| NCT00827177 Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors | Advanced Solid Tumors | P1 | Completed | 87 | Open-label | Treatment with ARQ 197 in combination with sorafenib |
| NCT00398840 A Study of ARQ 171 in Patients With Advanced Solid Tumors | Cancer | P1 | Terminated | 14 | Open-label | ARQ 171 |
| NCT02307162 SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects | Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder | P1 | Completed | 112 | RCT, Double-blind | RPL554, Placebo |
| NCT01496677 Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects | Healthy Subjects | P1 | Completed | 28 | RCT, Open-label | TR-701 FA 200 mg, TR-701 FA 200 mg |
| NCT00996957 Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma | Advanced Solid Tumors, Multiple Myeloma | P1 | Completed | 37 | Open-label | ACE-041 |
| NCT02650895 Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001) | Healthy Volunteers | P1 | Completed | 40 | RCT, Double-blind | Efprezimod alfa, Saline |
| NCT03006887 Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | Solid Tumors | P1 | Completed | 6 | Open-label | lenvatinib, pembrolizumab |
| NCT02516904 A Single Ascending Dose Study of CD101 IV in Healthy Subjects | Healthy | P1 | Completed | 32 | RCT, Double-blind | CD101 IV, Placebo |
| NCT02266706 Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010) | Proven or Suspected Gram-negative Bacterial Infection, Peri-operative Prophylaxis | P1 | Completed | 43 | Open-label | Ceftolozane/Tazobactam 1000/500 mg, Ceftolozane/Tazobactam 30/15 mg/kg, Ceftolozane/Tazobactam 20/10 mg/kg, Ceftolozane/Tazobactam 18/9 mg/kg, Ceftolozane/Tazobactam 12/6 mg/kg |
| NCT07839000 A Clinical Trial to Evaluate [14C]-MK-4208/[14C]-TERN-701 in Healthy Adult Male Participants (MK-4208-002/TERN701-1016) | Healthy | P1 | Completed | 8 | Open-label | TERN-701 |
| NCT01432717 Study of ACE-536 in Healthy Postmenopausal Women | Anemia | P1 | Completed | 40 | RCT, Double-blind | ACE-536 |
| NCT01156077 Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients | Bacterial Infection | P1 | Completed | 20 | Open-label | TR-701 FA, TR-701 FA |
| NCT02257489 Phase 1 Study of ACE-083 in Healthy Subjects | Musculoskeletal Diseases | P1 | Completed | 58 | RCT, Double-blind | ACE-083 |
| NCT05354349 Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023 | Healthy | P1 | Completed | 49 | RCT, Double-blind | PRA023 IV Low Dose, PRA023 SC, Placebo IV, Placebo SC, PRA023 IV High Dose |
| NCT03006926 A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | Hepatocellular Carcinoma | P1 | Completed | 104 | Open-label | lenvatinib, pembrolizumab (200 mg) |
| NCT01813448 A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects | Pharmacokinetics of Fidaxomicin, Healthy Subjects | P1 | Completed | 36 | RCT, Double-blind | Fidaxomicin, Placebo |
| NCT02476955 Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole | Solid Tumors, Ovarian Cancer | P1 | Terminated | 41 | Open-label | ARQ 092 + carboplatin + paclitaxel (Closed), ARQ 092 + paclitaxel (Closed), ARQ 092 + anastrozole |
| NCT02341599 Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects (MK-6183-001) | Healthy Volunteers, Renal Impairment | P1 | Completed | 40 | Open-label | MK-6183 |
| NCT00952887 A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women | Muscular Atrophy | P1 | Completed | 70 | RCT, Double-blind | ACE-031, Placebo |
| NCT01149720 Determination of the Relative Bioavailability of ARQ 197 Tablet Formulation With Capsule C Formulation as a Reference in Subjects With Advanced Solid Tumors | Solid Tumors | P1 | Completed | 24 | RCT, Open-label | Tivantinib (ARQ 197) Capsule, Tivantinib (ARQ 197) Tablet, Tivantinib (ARQ 197) Capsule D, oral |
| NCT01919125 Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008) | Hepatitis C, Chronic | P1 | Completed | 36 | Open-label | IDX719 |
| NCT01050283 A Study to Evaluate [18F]-FDG PET (Fluorodeoxyglucose-positron) in Patients With Pancreatic Cancer (MK-0000-144) | Advanced Pancreatic Adenocarcinoma | P1 | Terminated | 15 | Open-label | — |
| NCT02269423 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) | Ebola Virus | P1 | Completed | 39 | RCT, Double-blind | V920 |
| NCT03326986 Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001) | Pharmacokinetics, Cancer | P1 | Completed | 24 | RCT, Double-blind | MK-7252, Placebo |
| NCT04880213 Study of M5049 in Healthy Japanese and Caucasian Participants | Healthy | P1 | Completed | 36 | Open-label | M5049, M5049, M5049 |
| NCT00694083 Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) | Neoplasm | P1 | Completed | 13 | Open-label | Ridaforolimus |
| NCT00632931 A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) | Advanced Cancer Relapsed, Advanced Cancer Refractory | P1 | Completed | 25 | RCT, Single-blind | vorinostat, Comparator: placebo (unspecified) |
| NCT01032681 EMD 521873 in Advanced Solid Tumors, MTD Finding | Non-Hodgkin Lymphoma | P1 | Completed | 66 | Open-label | EMD 521873, EMD 521873, EMD 521873 |
| NCT04374877 Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors | Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma | P1 | Completed | 145 | Open-label | CHS-388, Pembrolizumab, Toripalimab |
| NCT03340766 Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) | P1 | Completed | 31 | Open-label | Blinatumomab, Pembrolizumab |
| NCT02512172 A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | Colorectal Cancer | P1 | Completed | 27 | RCT, Double-blind | Oral CC-486, Romidepsin, MK-3475 |
| NCT03188523 Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002) | HIV-1 Infection | P1 | Completed | 12 | Open-label | MK-8504 |
| NCT00902161 A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED) | Type 2 Diabetes Mellitus | P1 | Completed | 22 | RCT, Double-blind | MK0893, MK0893-matched Placebo, Propranolol Hydrochloride (HCL) |
| NCT06942741 A Study to Evaluate the Effect of Formulation and Food on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-011) | Healthy | P1 | Completed | 52 | RCT, Open-label | Calderasib OCT, Calderasib FCT |
| NCT01676753 Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer | Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer | P1 | Completed | 32 | Open-label | Dinaciclib, Pembrolizumab |
| NCT01731587 Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer | Non-small Cell Lung Cancer (NSCLC) Stage III | P1 | Withdrawn | — | Open-label | Cyclophosphamide (CPA) |
| NCT01385566 A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) | Herpes Zoster | P1 | Completed | 223 | RCT, Single-blind | ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous, ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous, ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal, ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal, Full Dose Intradermal Placebo, Intradermal Placebo |
| NCT01023737 Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | Malignant Solid Tumour | P1 | Completed | 72 | Open-label | Hydroxychloroquine, Vorinostat |
| NCT02586207 Pembrolizumab in Combination With CRT for LA-SCCHN | Head and Neck Cancer, Squamous Cell Carcinoma | P1 | Completed | 59 | Open-label | pembrolizumab (MK-3475), Cisplatin |
| NCT06643377 A Clinical Study of Enlicitide in Participants With Severe Renal Impairment (MK-0616-032) | Healthy, Renal Impairment | P1 | Completed | 27 | Open-label | Enlicitide |
| NCT02715700 Effects of Doravirine (MK-1439) on Methadone Pharmacokinetics in Methadone-Maintained Participants (MK-1439-045) | Human Immunodeficiency Virus (HIV) Infection | P1 | Completed | 14 | Open-label | Methadone, Doravirine |
| NCT00535236 A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002) | Herpes Zoster, Herpes Zoster-related Complications | P1 | Completed | 341 | RCT, Double-blind | V212, Placebo |
| NCT07086079 A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061) | Healthy | P1 | Completed | 12 | Open-label | DOR/ISL |
| NCT04722562 A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy Participants | Heart Failure | P1 | Completed | 27 | Open-label | Vericiguat (BAY1021189) |
| NCT01327313 A Study of EMD525797 in Solid Tumor Patients in Japan | Solid Tumor | P1 | Completed | 27 | Open-label | EMD525797, EMD525797, EMD525797, EMD525797 |
| NCT02392494 Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002) | Hepatitis C | P1 | Completed | 9 | Open-label | MK-1075 |
| NCT04609579 Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Advanced Solid Tumor, Advanced Lymphoma | P1 | Terminated | 27 | Open-label | SNX281, pembrolizumab |
| NCT04224480 Longitudinal Immune-phenotyping of HCC Following MK-3475 | Hepatocellular Carcinoma | P1 | Unknown | 8 | Open-label | Pembrolizumab |
| NCT00704054 A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED) | Solid Tumors | P1 | Completed | 15 | Open-label | ridaforolimus |
| NCT02938624 Anti PD-1 Neo-adjuvant Treatment for NSCLC | Non Small Cell Lung Carcinoma, Stage I | P1 | Completed | 28 | Open-label | Pembrolizumab 200 mg IV single dose, Pembrolizumab 200 mg IV twice interval 21 days, Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d, Pembrolizumab 100 mg I.V single dose |
| NCT06733688 A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043) | Healthy | P1 | Completed | 36 | RCT, Open-label | Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test) |
| NCT02938273 Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) | Carcinoma, Squamous Cell of Head and Neck | P1 | Completed | 10 | Open-label | avelumab, cetuximab |
| NCT06687759 A Study of Calderasib (MK-1084) Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006) | Healthy | P1 | Completed | 8 | Open-label | [14C]Calderasib |
| NCT06816030 A Clinical Study of MK-4482 in Chinese Healthy Male Participants (MK-4482-009) | Healthy | P1 | Completed | 16 | Open-label | MK-4482 |
| NCT03261401 First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Participants | Healthy | P1 | Completed | 88 | RCT, Double-blind | M5717, Placebo, M5717 |
| NCT03996473 Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases | Carcinoma, Non-Small-Cell Lung | P1 | Terminated | 8 | RCT, Open-label | Radium-223 dichloride (Xofigo, BAY 88-8223), Pembrolizumab |
| NCT06609161 A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044) | Healthy | P1 | Completed | 18 | RCT, Open-label | Tedizolid Phosphate Oral Formulation 1 (Reference), Tedizolid Phosphate Oral Formulation 2 (Test) |
| NCT01390441 A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002) | Rheumatoid Arthritis | P1 | Terminated | 100 | RCT, Double-blind | MK-8808, MabThera® (rituximab), Methotrexate, Rituxan® (rituximab), Methylprednisolone, Acetaminophen, Loratadine |
| NCT00393445 Exendin(9-39)Amide as a Glucagon-like Peptide-1 (GLP-1) Receptor Antagonist in Humans | Hyperglycemia | P1 | Completed | 6 | RCT, Single-blind | GLP-1 control, GLP-1 and Exendin(9-39) 300, saline control, GLP-1 and Exendin(9-39) 600, GLP-1 and Exendin(9-39) 900, GLP-1 and Exendin(9-39) 1200 |
| NCT04370873 Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006) | Pulmonary Hypertension | P1 | Completed | 22 | RCT, Double-blind | Frespaciguat, Placebo |
| NCT03311841 Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386) | Renal Insufficiency | P1 | Completed | 32 | Open-label | Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin |
| NCT00561418 Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma | Lymphoma, Small Intestine Cancer | P1 | Completed | 23 | Open-label | vorinostat |
| NCT00848718 A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003) | Locally Advanced, Metastatic Solid Tumors | P1 | Completed | 77 | Open-label | MK-2206, docetaxel, erlotinib, carboplatin, paclitaxel, corticosteroid |
| NCT00570310 Neuropathic Pain Syndrome Patient Study (MK-0000-072) | Neuralgia, Postherpetic, Diabetic Neuropathy | P1 | Completed | 104 | RCT, Double-blind | Comparator: pregabalin, Comparator: Placebo (unspecified) |
| NCT05656040 A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011) | End-Stage Renal Disease, End-Stage Kidney Disease | P1 | Completed | 14 | RCT, Single-blind | MK-2060, Placebo |
| NCT03881488 Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | Locally Advanced Solid Tumor, Metastatic Cancer | P1 | Terminated | 100 | Open-label | CTX-471, Pembrolizumab (KEYTRUDA®) |
| NCT01054300 Effects of Once and Twice Daily Dosing Regimen of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-040) | Diabetes Mellitus, Type 2, Adult | P1 | Completed | 52 | RCT, Double-blind | Ertugliflozin 2 mg single dose, Ertugliflozin 2 mg split into twice daily, Ertugliflozin 4 mg single dose, Ertugliflozin 4 mg split into twice daily, Placebo |
| NCT01071018 A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) | Solid Tumors | P1 | Completed | 24 | Open-label | MK2206 every other day, MK2206 once weekly |
| NCT02314923 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) | Ebola Virus | P1 | Completed | 513 | RCT, Double-blind | V920 Vaccine |
| NCT03629223 Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib | Healthy | P1 | Completed | 66 | RCT, Open-label | Tepotinib TF2, Tepotinib TF3 |
| NCT01396005 A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123) | Hepatitis C Virus | P1 | Completed | 21 | Open-label | boceprevir, methadone, buprenorphine/naloxone |
| NCT06894771 A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001) | Malignant Neoplasm | P1 | Completed | 5 | Open-label | MK-4700, Pembrolizumab |
| NCT00768170 MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028) | Asthma | P1 | Completed | 10 | Open-label | MK0633 |
| NCT03546608 Tepotinib Hepatic Impairment Trial | Hepatic Impairment | P1 | Completed | 18 | Open-label | Tepotinib |
| NCT00701389 Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) | Migraine Disorders | P1 | Completed | 24 | RCT, Double-blind | telcagepant potassium, sumatriptan, sumatriptan placebo, telcagepant potassium placebo |
| NCT01948986 Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009) | Renal Impairment, Type 2 Diabetes Mellitus | P1 | Completed | 36 | Open-label | Ertugliflozin |
| NCT00911469 Study of AS902330 (rhFGF-18) Administered Intra-articularly in Patients With Knee Primary Osteoarthritis Who Are Candidates for Total Knee Replacement | Knee Osteoarthritis | P1 | Completed | 73 | RCT, Double-blind | AS902330, Placebo |
| NCT00863590 A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers | Osteoporosis | P1 | Completed | 24 | RCT, Double-blind | odanacatib, Comparator: odanacatib (Panel B), Comparator: odanacatib (Panel C), Comparator: odanacatib (Panel D) |
| NCT02630823 MK-3475 Immunotherapy in Endometrial Carcinoma | Endometrial Cancer, Endometrial Carcinoma | P1 | Completed | 10 | Open-label | MK-3475, Paclitaxel (standard of care), Carboplatin (standard of care) |
| NCT01504165 Pharmacokinetics in Subjects With Renal Impairment | Renal Impairment | P1 | Completed | 32 | Open-label | cilengitide 2000mg, cilengitide 2000mg, cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg |
| NCT00511667 A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005) | Type 2 Diabetes Mellitus | P1 | Completed | 70 | RCT, Double-blind | MK0941, Comparator: Placebo |
| NCT04336098 Study of SRF617 in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | Completed | 85 | Open-label | SRF617, Gemcitabine, Albumin-Bound Paclitaxel, Pembrolizumab |
| NCT00836498 A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027) | Rotavirus | P1 | Terminated | 66 | RCT, Double-blind | Comparator: RotaTeq, Comparator: Placebo, Comparator: RotaTeq + Placebo |
| NCT00696709 A Study to Test the Safety and Antibody Response of V212 in Healthy Adults (V212-004)(COMPLETED) | Herpes Zoster | P1 | Completed | 290 | RCT, Double-blind | Comparator: V212, Comparator: Placebo |
| NCT00565006 A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED) | Ambulatory Blood Pressure | P1 | Completed | 22 | — | MK0859 |
| NCT00857311 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED) | Hepatitis C | P1 | Completed | 17 | RCT, Double-blind | MRKAd5 HIV-1 gag vaccine (V520), Comparator: Placebo, Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed, MRKAd5 HIV-1 gag vaccine (V520) |
| NCT06647628 A Clinical Study of MK-1708 in Healthy Elderly Participants (MK-1708-005) | Healthy | P1 | Completed | 16 | RCT, Double-blind | MK-1708, Placebo |
| NCT03745144 Effects of Cladribine Tablets on the PK of Microgynon® | Relapsing Multiple Sclerosis (RMS) | P1 | Completed | 28 | RCT, Double-blind | Cladribine, Placebo, Microgynon® |
| NCT01390428 Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Grazoprevir (MK-5172-013) | Hepatitis C | P1 | Completed | 50 | Open-label | Grazoprevir |
| NCT01335607 A Open-label Study to Evaluate the Relative Bioavailability of Samatasvir (IDX184) and Food Effect in Healthy Male Participants (MK-2355-006) | Hepatitis C | P1 | Completed | 12 | RCT, Open-label | Samatasvir tablet, Samatasvir capsule |
| NCT04659629 NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer | Solid Tumor, Advanced Solid Tumor | P1 | Completed | 59 | Open-label | NL-201, Pembrolizumab Injection [Keytruda] |
| NCT01512693 Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070) | Hepatic Insufficiency | P1 | Completed | 17 | Open-label | MK-0822 |
| NCT04695847 M1231 in Participants With Solid Tumors | Metastatic Solid Tumors, Esophageal Cancer | P1 | Completed | 23 | Open-label | M1231, M1231 |
| NCT06442436 A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015) | Hepatic Impairment (HI) | P1 | Completed | 24 | Open-label | Nemtabrutinib |
| NCT02318771 Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer | Head and Neck Squamous Cell Carcinoma, Metastatic Renal Cell Cancer | P1 | Completed | 41 | RCT, Open-label | MK-3475 |
| NCT04730635 Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413) | Alzheimer's Disease, Mild Cognitive Impairment | P1 | Completed | 44 | RCT, Double-blind | Donepezil, Placebo |
| NCT06625840 A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004) | Healthy | P1 | Completed | 16 | RCT, Double-blind | MK-1167, Placebo |
| NCT02011490 Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105) | Renal Insufficiency, Renal Impairment | P1 | Completed | 33 | Open-label | sugammadex |
| NCT05311618 Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | Pancreatic Cancer, Breast Cancer | P1 | Unknown | 71 | Open-label | NGM438, Pembrolizumab (KEYTRUDA ®) |
| NCT01118676 Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer | Locally Advanced Non Small Cell Lung Cancer (NSCLC) | P1 | Completed | 14 | Open-label | cilengitide, radiochemotherapy |
| NCT04037748 Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form | Healthy | P1 | Completed | 72 | RCT, Open-label | Puran T4®, Eutirox® |
| NCT01209741 Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED) | Migraine | P1 | Completed | 48 | RCT, Open-label | telcagepant potassium, MK-0974 5Mo5C, MK-0974 12Mo5C |
| NCT00541229 Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED) | Type 2 Diabetes | P1 | Completed | 103 | RCT, Double-blind | sitagliptin phosphate, sitagliptin phosphate, Comparator: Placebo |
| NCT00418366 A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008) | Renal Insufficiency, Hemodialysis | P1 | Completed | 24 | Open-label | MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days |
| NCT00112372 Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED) | Cancer | P1 | Completed | 147 | RCT, Open-label | Ridaforolimus |
| NCT01678807 Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008) | Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal | P1 | Completed | 195 | RCT, Double-blind | MK-8237 6 DU, MK-8237 12 DU, Placebo |
| NCT00966030 Bioequivalence of the Tablet and Liquid-Filled Capsule Forms of MK0974 (0974-042) | Migraine | P1 | Completed | 50 | RCT, Open-label | MK0974 tablet, Comparator: MK0974 liquid filled capsule |
| NCT07677163 A Clinical Trial of MK-1403 in Healthy Participants (MK-1403-007) | Healthy | P1 | Completed | 15 | RCT, Open-label | MK-1403 formulation (FM) 1 + additive, MK-1403 FM2 + additive |
| NCT01025791 A Single Dose Study of MK-8266 (MK-8266-001) | Hypertension | P1 | Completed | 25 | RCT, Double-blind | MK-8266 0.1 mg, MK-8266 1.0 mg, Placebo |
| NCT00100152 A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia | P1 | Terminated | 50 | Open-label | MK0752, (Notch Inhibitor) |
| NCT01593735 A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1) | Hepatitis C | P1 | Completed | 30 | RCT, Double-blind | MK-2748, Placebo |
| NCT02675946 CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Solid Tumors, GI Cancer | P1 | Unknown | 72 | Open-label | CGX1321, Pembrolizumab, encorafenib, cetuximab |
| NCT01348880 Vardenafil ODT (Orally Disintegrating Tablet) - Nifedipine Interaction Study | Erectile Dysfunction | P1 | Completed | 42 | RCT, Double-blind | Vardenafil ODT, (Staxyn, BAY38-9456), Placebo |
| NCT04647708 Study of M5049 in CLE and SLE Participants | Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus | P1 | Completed | 25 | RCT, Double-blind | M5049, M5049, M5049, Placebo |
| NCT07232589 A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022) | Healthy | P1 | Completed | 26 | Open-label | Nemtabrutinib, Diltiazem |
| NCT01324440 Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) | Staphylococcal Infections | P1 | Completed | 64 | RCT, Double-blind | V710 (30 µg) with MAA, V710 (30 µg) without MAA |
| NCT05064488 Drug-Drug Interaction Study of Evobrutinib and Transporter Substrates | Healthy | P1 | Completed | 40 | Open-label | Evobrutinib (45mg), Digoxin (0.25mg), Metformin (10mg), Rosuvastatin (10mg), Sumatriptan (25mg) |
| NCT03566810 Glucophage Extended Release (GXR) China Bioequivalence Study (Nantong - Darmstadt) | Healthy | P1 | Completed | 54 | RCT, Open-label | Test GXR, Reference GXR |
| NCT04920383 ALPN-202 With PD-1 Inhibition in Advanced Malignancies | Advanced Solid Tumor, Lymphoma | P1 | Terminated | 29 | Open-label | ALPN-202, pembrolizumab KEYTRUDA® |
| NCT01329913 Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003) | Hepatitis C | P1 | Completed | 36 | RCT, Double-blind | MK-6325, Placebo to MK-6325, MK-6325, Placebo to MK-6325, MK-6325, Placebo to MK-6325 |
| NCT01075451 Antimicrobial Drug Use and Resistant Staphylococcus Aureus | Staphylococcus Aureus | Completed | 41 | — | — | |
| NCT03317366 Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies | Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS) | NO_LONGER_AVAILABLE | — | — | ARQ 092 | |
| NCT07487441 Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept. | Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension | Not Yet Recruiting | 30 | — | — | |
| NCT01143259 Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use | Ileus | N/A | Completed | 274 | RCT, Double-blind | Alvimopam, 300 mg Polyethylene |
| NCT00492193 Early Post-Op Recovery After Partial Large Bowel Resection | Diverticulitis, Colon Polyps | Completed | 139 | — | — | |
| NCT01150760 Clinical Outcomes After Bowel Resection in Patients Receiving Alvimopan Versus Patients Not Receiving Alvimopan in the Premier Perspective Database | Ileus | Completed | 7,050 | — | Alvimopan | |
| NCT01025271 Cerebrospinal Fluid Pharmacokinetics of Daptomycin | Meningitis | N/A | Terminated | 2 | Open-label | Daptomycin |
| NCT01216540 Vancomycin-Associated Nephrotoxicity | Nephrotoxicity | Completed | 398 | — | — | |
| NCT02888197 Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization | Candidiasis, Vulvovaginal, Yeast Infection | Completed | 32 | — | — | |
| NCT02762721 Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma | Completed | 131 | — | — | |
| NCT01813500 Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients | Crohn's Disease, Ulcerative Colitis | Completed | 400 | — | — | |
| NCT07878442 Tailored Vaccine Messaging for Parents/Caregivers of Adolescents | Vaccine Confidence, Adolescent Vaccination | N/A | Not Yet Recruiting | 2,000 | RCT, Open-label | — |
| NCT02097953 Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin | Drug Interactions, Pharmacokinetics | Early P1 | Completed | 12 | Open-label | Daptomycin, Rifampin |
| NCT00261807 Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections | Fasciitis, Necrotizing, Severe Necrotizing Skin and Soft Tissue Infections | N/A | Completed | 25 | Open-label | Daptomycin 6mg/kg/day |
| NCT01012089 Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease | Chronic Kidney Disease, Bacterial Infection | N/A | Completed | 6 | Open-label | Daptomycin |
| NCT02597790 A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects | HIV, Hepatitis C | Completed | 87 | — | — | |
| NCT01671605 Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation | Chronic Kidney Disease, Cardiovascular Disease | Completed | 103 | — | — | |
| NCT00725010 Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) | Glioblastoma | Completed | 64 | — | Temozolomide | |
| NCT00723827 Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2) | Glioblastoma, Glioma | Completed | 682 | — | Temozolomide | |
| NCT00725842 Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed) | Hepatitis C, Hepatitis C, Chronic | Terminated | 97 | — | Peg-IFN alfa-2b, Ribavirin | |
| NCT04167761 Ertugliflozin: Cardioprotective Effects on Epicardial Fat | Cardiovascular Diseases, Atherosclerosis | Early P1 | Completed | 61 | Open-label | Ertugliflozin |
| NCT01142453 An Observational Study Evaluating Therapy Optimisation Using High-frequency and High-dosage Administration of Interferon-beta (Rebif®) in Multiple Sclerosis (MS) Patients | Relapsing-Remitting Multiple Sclerosis | Completed | 231 | — | Interferon beta 1a | |
| NCT00658827 Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis | Inflammatory Bowel Disease | Completed | 370 | — | — | |
| NCT06639386 Vaccine Confidence Study Among Historically Marginalized Racial and Ethnic Groups | Vaccine Hesitancy, Vaccine Refusal | Completed | 68 | — | — | |
| NCT01355003 GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) | Papillomavirus Infections | Terminated | 1,080 | — | — | |
| NCT01164605 Pilot Study of Raltegravir Lipodystrophy IISP | HIV Infection | N/A | Unknown | 30 | Open-label | Raltegravir |
| NCT01643473 Tailored Approaches to Improve Medication Adherence | Hypertension | N/A | Completed | 42 | RCT, Single-blind | — |
| NCT03854734 Healthy, Immunized Communities Study | Vaccine Hesitancy, Communicable Diseases in Children | N/A | Completed | 148 | RCT, Single-blind | — |
| NCT00705614 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) | Crohn's Disease | Completed | 2,662 | — | Remicade | |
| NCT01517529 Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations | Hepatitis C | Completed | 10 | — | — | |
| NCT00704522 Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) | Hepatitis C, Chronic, Hepacivirus | Completed | 601 | — | Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908) | |
| NCT04259931 PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA | Clostridium Difficile Infection | Unknown | 50 | — | — | |
| NCT01382407 Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab | Colorectal Cancer Metastatic | Completed | 100 | — | Cetuximab | |
| NCT07348250 Open-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease | Parkinson's Disease (PD), Parkinson's Disease | Early P1 | Terminated | 16 | Open-label | [18F]MK-0947 |
| NCT01293123 Raltegravir Cerebrospinal Fluid Pharmacodynamic Study in HIV-Infected Individuals | HIV | N/A | Terminated | 2 | RCT, Open-label | Raltegravir, Efavirenz |
| NCT00772473 Correlation of Calcitonin Gene-Related Peptide (CGRP) Levels in Saliva With the Evolution of an Attack of Migraine | Headache, Migraine | Completed | 34 | — | — | |
| NCT01632254 Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque | Atherosclerosis | Unknown | 30 | — | — | |
| NCT00904644 Raltegravir in the Swiss HIV Cohort Study | HIV Infection | Completed | 200 | — | Raltegravir | |
| NCT00588471 Effect of Acute Statin Treatment in Patients Undergoing Percutaneous Coronary Intervention | Coronary Artery Disease | N/A | Terminated | 57 | RCT, Double-blind | Simvastatin, Placebo |
| NCT04196777 Audit-and-feedback to Improve Antimicrobial-prescribing Among Urologists | Urologic Diseases, Antibacterial Drug Adverse Reaction | N/A | Completed | 525 | Open-label | — |
| NCT06704308 Parents' HPV Stories | HPV Vaccination | N/A | Not Yet Recruiting | 58 | Open-label | — |
| NCT00724854 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) | Hepatitis C, Chronic, Hepatitis C | Completed | 1,146 | — | PegIntron (peginterferon alfa-2b; SCH 54031), Rebetol (ribavirin; SCH 18908) | |
| NCT00724373 Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol (Study P05269)(COMPLETED) | Hepatitis C, Chronic | Completed | 442 | — | Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908) | |
| NCT01423760 Common Safety Follow-up Trial of Tecemotide (L-BLP25) | Non-Small Cell Lung Cancer, Multiple Myeloma | N/A | Terminated | 27 | Open-label | Tecemotide |
| NCT00723710 Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) | Melanoma | Completed | 299 | — | Intron A (interferon alfa-2b; SCH 30500) | |
| NCT01065766 Sitagliptin/Metformin (JANUMET) Re-examination Study (0431A-182) | Type 2 Diabetes Mellitus | Completed | 4,065 | — | Sitagliptin/metformin | |
| NCT01472575 Impact of Rotavirus Vaccine Introduction for South Australian Children | Viral Gastroenteritis Due to Rotavirus, Gastroenteritis | Unknown | 1,200 | — | — | |
| NCT04947111 Serological Study of Dengue and Characterization of Immune Response in Ten Endemic and Non-Endemic Cities in Mexico | Dengue | N/A | Unknown | 1,960 | Open-label | — |
| NCT02496832 A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo | Pancreatic Adenocarcinoma, Advanced Disease | N/A | Withdrawn | — | Open-label | 18F-Fluoroazomycin arabinoside |
| NCT01293656 Study of Participants With Crohn's Disease and Ulcerative Colitis in Eastern Europe, Middle East, and North Africa (P08166) | Inflammatory Bowel Disease, Crohn's Disease | Withdrawn | — | — | — | |
| NCT00394602 Chemoradiation-Induced Nausea and Emesis: Quality of Life | Gastric Cancer, Pancreatic Cancer | Terminated | 207 | — | — | |
| NCT00723879 Adherence in Patients Receiving PegIntron and Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04206) | Hepatitis C, Chronic, Hepacivirus | Terminated | 115 | — | Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908) | |
| NCT01134640 A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | Metastatic Colorectal Cancer | Completed | 286 | — | — | |
| NCT01836718 Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation | Hepatitis C Virus, Liver Transplantation | Unknown | 20 | — | — | |
| NCT02599220 Clinical Outcomes and Cost of Gram Negative Bacteremia | Gram-negative Bacteremia, Bacteremia | Completed | 2,000 | — | — | |
| NCT01581710 Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children. | Mild Persistent Asthma | N/A | Completed | 32 | RCT, Double-blind | Montelukast to placebo, Placebo to montelukast |
| NCT01986686 Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis | Diverticulitis | N/A | Completed | 107 | RCT, Open-label | — |
| NCT00641641 The Effect of Raltegravir on HIV Decay During Primary and Chronic Infection | HIV Infection | N/A | Completed | 16 | Open-label | Tenofovir + emtricitabine + raltegravir. |
| NCT00572832 Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting | Human Papillomavirus Infection | N/A | Completed | 200 | RCT, Open-label | Quadrivalent human papillomavirus vaccine on-time administration, Quadrivalent human papillomavirus vaccine delayed administration |
| NCT00723632 Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) | Hepatitis C, Chronic, Hepatitis C | Completed | 901 | — | peginterferon alfa-2b, ribavirin | |
| NCT04934800 Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS) | Multiple Sclerosis | Completed | 256 | — | Cladribine | |
| NCT01174147 A Laboratory-based Surveillance Study of Candida Bloodstream Infections (MK-0991-093) | Candidemia | Completed | 436 | — | — | |
| NCT01349920 Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (P08143) | Crohn Disease | Completed | 15 | — | Infliximab | |
| NCT03883568 A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis | Knee Osteoarthritis | Completed | 297 | — | — | |
| NCT00738725 BioImage Study: A Clinical Study of Burden of Atherosclerotic Disease in an At-Risk Population | Plaque, Atherosclerotic Disease | Completed | 7,687 | — | — | |
| NCT01173068 An Observational Study of Ertapenem in Outpatient Parenteral Antibiotic Therapy (OPAT) for Complicated Urinary Tract Infections. | Urinary Tract Infections | Unknown | 60 | — | Ertapenem | |
| NCT01087073 Improving Diabetes Care and Outcomes on the South Side of Chicago | Diabetes Mellitus | N/A | Completed | 6,209 | Open-label | — |
| NCT01814722 Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266) | Human Immunodeficiency Virus | Terminated | 63 | — | — | |
| NCT01085916 Prevalence of Asthma and Rhinitis Symptoms Among Secondary School Students in Saudi Arabia | Asthma, Rhinitis | Unknown | 4,000 | — | — | |
| NCT01062048 Januvia Re-examination Study (MK-0431-181) | Type 2 Diabetes Mellitus | Completed | 3,483 | — | Sitagliptin, Sulfonylurea, Insulin | |
| NCT05761509 "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk" | HIV Infections | Completed | 226 | — | Doravirine | |
| NCT03244176 Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study | Lymphomas Non-Hodgkin's B-Cell | Early P1 | Completed | 28 | Open-label | Avelumab |
| NCT00421018 Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK) | Allergic Asthma | N/A | Completed | 187 | RCT, Double-blind | Single corticosteroid inhalers and Singulair |
| NCT00430287 Does the Optic Disc Grading Done Visually by Your Doctor Agree With Optic Nerve Testing Which is Done by Machines? | Open Angle Glaucoma | Completed | 101 | — | — | |
| NCT00704717 Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) | Hepatitis C, Chronic, Hepatitis C | Completed | 185 | — | PegIntron (peginterferon alfa-2b; SCH 54031) pen, Rebetol (ribavirin; SCH 18908) | |
| NCT01617018 Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis | Psoriasis | Completed | 4,613 | — | — | |
| NCT01110993 An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF) | Multiple Sclerosis, Relapsing-Remitting | Completed | 65 | — | — | |
| NCT01133509 A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study | Genital Human Papilloma Virus Infection | N/A | Unknown | 100 | Open-label | Gardasil |
| NCT01109108 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage | Nasopharyngeal Carriage of S. Pneumoniae | Completed | 9,000 | — | — | |
| NCT02194608 Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347) | Type 2 Diabetes Mellitus | N/A | Completed | 500 | RCT, Open-label | — |
| NCT01138813 Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145) | Glioma | Completed | 8 | — | — | |
| NCT01476150 Prevalence and Predictors of Osteoporosis in the Beijing's Urban Population | Osteoporosis | Unknown | 10,000 | — | — | |
| NCT03394196 RESIST-2: 2nd-line ART for HIV-2 Infection | HIV-2 Infection | N/A | Terminated | 152 | Open-label | 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Tenofovir DF 300mg QD + Emtricitabine 200mg QD + Darunavir 600mg BID-Ritonavir 100mg BID +Raltegravir 400mg BID) |
| NCT01718860 Effects of Postoperative Residual Paralysis on Hospital Costs | Residual Paralysis, Post-Anesthesia | Unknown | 3,000 | — | — | |
| NCT00562991 Monitoring Asthma Treatment Using Exhaled Nitric Oxide | Asthma | Completed | 99 | — | — |